STATISTICAL ANALYSIS PLAN
Study Title: A Phase 3b Open -label Study  to Evaluate the Safety , Tolerability , 
Pharmacokinetics and Efficacy  of E/C/F/TAF Fixed Dose 
Combination (FDC) in HIV -
1 Infected Subjects on Chronic 
Hemodialy sis
Name of Test Drugs: Elvitegravir/Cobicistat/Emtricitabine/Tenof ovir Alafenamide 
(E/C/ F/TAF )Fixed -Dose Combination
Bictegravir /Emtricitabine /Tenofovir alafenamid e (B/F/TAF)
Fixed -Dose Combination
Study Number: GS-US-292-1825
Protocol Version: Amendment 2.1
Protocol Date: 01 May  2018
Analysis Type: Final
Analysis Plan Version: Version 1
Analysis Plan Date: 02 December 2019
Analysis Plan Author:
CONFIDENTIAL AND PROPRIETARY INFORMA TION
PPD(rJ GILEAiJ 
-
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 2 02 December 2019TABLE OF CONTE NTS
STATISTICAL ANALYSIS PLAN .............................................................................................................................. 1
TABLE OF CONTENTS .............................................................................................................................................. 2
LIST OF IN- TEXT TABL ES........................................................................................................................................ 4
LIST OF ABBREVIATIONS ........................................................................................................................................ 5
1. INTRODUCTION ................................................................................................................................................ 7
1.1. Study Objectives ...................................................................................................................................... 7
1.2. Study Design ............................................................................................................................................ 7
1.3. Sample Size and Pow er.......................................................................................................................... 10
2. TYPE OF PLANNED ANAL YSIS .................................................................................................................... 11
2.1. Data Monitoring Committee Analyses ................................................................................................... 11
2.2. Week 24 Analysis .................................................................................................................................. 11
2.3. Week 48 Analysis .................................................................................................................................. 11
2.4. Week 96 Analysis .................................................................................................................................. 11
2.5. Final Analysis ........................................................................................................................................ 11
3. GENERAL CONSIDERATIO NS FOR DATA ANALYSES ............................................................................ 12
3.1. Analysis Sets .......................................................................................................................................... 13
3.1.1. All Enrolled Subjects Analysis Set ....................................................................................... 13
3.1.2. B/F/TAF Enrolled Subjects Analysis Set ............................................................................. 13
3.1.3. E/C/F/TAF Full Analysis Set ............................................................................................... 13
3.1.4. B/F/TAF Full Analysis Set ................................................................................................... 13
3.1.5. E/C/F/TAF Safety Analysis Set ............................................................................................ 13
3.1.6. B/F/TAF Safety Analysis Set ............................................................................................... 13
3.1.7. B/F/TAF Plasma PK Analysis Set ........................................................................................ 13
3.2. Subject Grouping ................................................................................................................................... 14
3.3. Strata and Covariates .............................................................................................................................. 14
3.4. Examination of Subject Subgroups ........................................................................................................ 14
3.5. Multiple Comparisons ............................................................................................................................ 14
3.6. Missing Data and Outliers ...................................................................................................................... 14
3.6.1. Missing Data ........................................................................................................................ 14
3.6.2. Outliers ................................................................................................................................. 14
3.7. Data Handling Conventions and Transformations ................................................................................. 15
3.8. Analysis Windows ................................................................................................................................. 15
3.8.1. Definition of Study Day ....................................................................................................... 15
3.8.2. Analysis Windows ................................................................................................................ 16
3.8.3. Selection of Data in the Event of Multiple Records in a Window ....................................... 20
4. SUBJECT DISPOSITION .................................................................................................................................. 22
4.1. Subject Enrollment and Disposition ....................................................................................................... 22
4.1.1. Subject Enrollment ............................................................................................................... 22
4.1.2. Subject Disposition .............................................................................................................. 22
4.2. Extent of Study Drug Exposure and Adherence ..................................................................................... 23
4.2.1. Duration of Exposure to E/C/F/TAF Study Drug ................................................................. 23
4.2.2. Duration of Exposure to B/F/TAF Study Drug .................................................................... 23
4.2.3. Adherence with Study Drug ................................................................................................. 23
4.3. Protocol Deviations ................................................................................................................................ 24
5. BASELINE CHARACTERIS TICS .................................................................................................................... 25
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 3 02 December 20195.1. Dem ographics and Baseline Characteristics .......................................................................................... 25
5.2. Baseline Disease Characteristics ............................................................................................................ 25
5.3. Medical History ...................................................................................................................................... 26
6. ANALYSES OF PRIMARY ENDPOINT .......................................................................................................... 27
6.1. Definition of the Primary Endpoint ........................................................................................................ 27
7. EFFICACY ANALYSES ................................................................................................................................... 28
7.1. Efficacy Endpoints as Secondary Study Endpoints ................................................................................ 28
7.2. Analysis of Efficacy Endpoints .............................................................................................................. 28
7.2.1. Analysis of the Proportion of Subjects with HIV -1 RNA < 50copies/m L 
at Week 96 as Determined by US FDA -defined Snapshot Algorithm ................................. 28
7.2.2. Analysis of Other Efficacy Endpoints .................................................................................. 29
7.3. Changes From Protocol -Specified Efficacy Analyses ............................................................................ 30
8. SAFETY ANALYSES ........................................................................................................................................ 31
8.1. Adverse E vents Up to Week 96 ............................................................................................................. 31
8.2. Analysis of Adverse Events Up to Week 96 .......................................................................................... 32
8.3. Adverse Events and Deaths .................................................................................................................... 32
8.3.1. Adverse Event Dictionary .................................................................................................... 32
8.3.2. Adverse Event Severity ........................................................................................................ 32
8.3.3. Relationship of Adverse Events to Study Drug .................................................................... 32
8.3.4. Serious Adverse Events ........................................................................................................ 33
8.3.5. Treatment- Emergent Adverse Events ................................................................................... 33
8.3.6. Summaries of Adverse Events and Deaths ........................................................................... 34
8.3.7. Additional Analysis of Adverse Events ............................................................................... 35
8.4. Laboratory Evaluations .......................................................................................................................... 37
8.4.1. Summaries of Numeric Laboratory Results ......................................................................... 37
8.4.2. Graded Laboratory Values ................................................................................................... 38
8.4.3. Metabolic Laboratory Evaluations ....................................................................................... 40
8.4.4. Liver -Related Laboratory Evaluations ................................................................................. 41
8.5. Vital Signs and Body Weight ................................................................................................................. 42
8.6. Prior and Concomitant Medications ....................................................................................................... 42
8.6.1. Nonstudy -Drug Antiretroviral (ARV) Medications ............................................................. 42
8.6.2. Concomitant Non -ARV Medications ................................................................................... 43
8.7. Electrocardiogram Results ..................................................................................................................... 43
8.8. Healthcare Utilization Assessment ......................................................................................................... 43
8.9. Other Safety Analysis ............................................................................................................................ 44
8.10. Changes From Protocol -Specified Safety Analyses ............................................................................... 44
9. PHARMACOKINETIC ANAL YSES ................................................................................................................ 45
10. PATIENT REPORTED OUTCOMES ................................................................................................................ 46
10.1. Medication Adherence Questionnaire .................................................................................................... 46
10.2. HIV Treatment Satisfaction Questionnaire ............................................................................................ 47
10.3. SF-36 (Version 2) Health Survey ........................................................................................................... 48
10.3.1. Scoring the SF -36................................................................................................................. 48
10.3.2. SF-36 Statistical Analysis Method ....................................................................................... 48
11. REFERENCES ................................................................................................................................................... 49
12. SOFTWARE ....................................................................................................................................................... 50
13. SAP REVISION .................................................................................................................................................. 51
14. APPENDICES .................................................................................................................................................... 52
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 4 02 December 2019Appendix 1. Study Procedures Table (E/C/F/TAF Phase) .......................................................................... 53
Appendix 2. Study Procedures Table (Open Label Rollover Extension) .................................................... 56
Appendix 3. Flow chart of US FDA -defined Snapshot Algorithm for Switch Trial .................................... 58
Appendix 4. Cardiovascular or Cerebrovascular Events ............................................................................. 59
Appendix 5. Hepatic Events ........................................................................................................................ 60
Appendix 6. TFL Mocks ............................................................................................................................. 61
Appendix 7. Programming Specifications ................................................................................................... 68
LIST OF IN -TEXT TABL ES
Table 3-1. Analysis Windows for HIV -1 RNA, CD4 Cell Count, CD4%, Hematologya, 
Chemistryb, eGFR CG, Vital Signs, Weight, Visual Analogue Scale (VAS), and 
Healthcare Utilization Assessment (E/C/F/TAF Phase) ......................................................... 17
Table 3-2. Analysis Windows for Fasting Glucose and Lipid Panel (E/C/F/TAF Phase) ....................... 17
Table 3-3. Analysis Windows for prothrombin time and INR (E/C/F/TAF Phase) ................................. 18
Table 3-4. Analysis Windows for SF -36 and HIV -TSQc (E/C/F/TAF Phase) ........................................ 18
Table 3-5. Analysis Windows for HIV -TSQs (E/C/F/TAF Phase) .......................................................... 18
Table 3-6. Analysis Windows for Safety ECG (E/C/F/TAF Phase) ........................................................ 19
Table 3-7. Analysis Windows for HIV -1 RNA, CD4 Cell Count, CD4%, Hematologya, 
Chemistryb, eGFR CG, Vital Signs, and Weight (B/F/TAF OL Extension Phase) ................... 19
Table 3-8. Analysis Windows for Fasting Glucose and Lipid Panel (B/F/TAF OL Extension 
Phase) ..................................................................................................................................... 19
Table 3-9. Analysis Windows for SF -36 and HIV -TSQ (B/F/TAF OL Extension Phase) ...................... 20
Table 3-10. Analysis Windows for Safety ECG (B/F/TAF OL Extension Phase) .................................... 20
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 5 02 December 2019LIST OF ABBREVIATIONS
ABC abacavir
AE adverse event
AIDS acquired immun odeficiency syndrome
ALP alkaline phosphatase
ALT alanine aminotransferase
ARV antiretroviral 
AST aspartate aminotransferase
B/F/TAF bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mgfixed -dose
combination, Biktarvy®
BMI body mass index
BLQ below  the limit of quantitation
CDER Center for Drug Evaluation and Research
CG Cock croft-Gault 
CI confidence interval 
COBI cobicistat (Tybost®)
CPK creatine phosphokinase
CRF case report form
CV coefficient of variation
E/C/F/TAF single -tablet regimen of elvitegravir (EVG ) 150 mg/ cobicistat (COBI) 150 mg / 
emtricitabine (FTC) 200 mg/tenofovir alafenamide (TAF) 10mg ; coformulated; 
Genvoya®
ECG electrocardiogram
eCRF electronic case report form
eGFR estimated glomerular filtration rate
eGFR CG estimated glomerular filtration rate calculated using the Cockcroft -Gault formula
ESDD early study drug discontinuation
ESRD end stage renal disease
EVG elvitegravir
FAS Full Analysis Set
FDA Food and Drug Administration
FDC fixed -dose combination
FTC emtricitabine (Emtriva®)
GFR glomerular filtration rate
GSI Gilead Sciences, Inc.
HD hemodialysis
HDL high-density lipoprotein
HIV-1 human immunodeficiency virus (type 1) 
HLGT high level group term s
HLT high level term
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 6 02 December 2019IDMC independent data monitoring committee
INR international normalized ratio of prothrombin time
LOCF last observation carried forward 
LDL low-density lipoprotein
LLT lowestlevel term
LLOQ lower limit of quantitation
MedDRA Medical Dictionary for Regulatory Activities
OL open label
PBMC peripheral blood mononuclear cell
PK pharmacokinetic
PT preferred term
PTH parathyroid hormone
Q quartile
Q1 first quartile
Q3 third quartile
RNA ribonucleic acid
SAE serious adverse event
SAP statistical analysis plan
Scr serum creatinine concentration
SD standard deviation 
SMQ Standardised MedDRA Query
SOC system organ class
STB elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate, coformulated; Stribild®
STR single -tablet regimen 
TAF tenofovir alafenamide
TDF tenofovir disoproxil fumarate (Viread®)
TEAE Treatment- emergent adverse event
TFL tables, figures, and listings
TFV tenofovir
ULN upper limit of normal
VAS visual analogue scale
WHO World Health Organization
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 7 02 December 20191. INTRODUCTION
This statistical analy sis plan (SAP) describes the statistical analy sismethods and data 
presentations to be used in tables, figures, and listings (TFLs) of the final analy sisfor Study  
GS-US-
292-1825, which will be performed when all subjects have completed the study or 
prematurel y discontinued from the study . This SAP is based on the study  Protocol Amendment 
2.1,dated 01May 2018, and electronic case report form (eCRF). The SAP will be finalized 
before database finalization
. Any  changes made to the anal yses after the finalization of the SAP 
will be documented in the final clinical study  report. Analy ses that were pe rformed as part of 
interim clinical study  reports will not be repeated for the final anal ysis unless otherwise 
specified.
1.1.
Study Objectives
The pri mary  objective of this study  is as follows: 
To evaluate the safet y and tolerability  of elvitegravir /cobicistat /emtricitabine/ tenofovir 
alafenamide (EVG/COBI/FTC/TAF; E/C/F/TAF ) fixed -dose combination (FDC )in HIV -1 
infected adults with end stage renal disease ( ESRD )on chronic hemodialy sis(HD) at 
Week 48
The secon dary objective sof this study  areas follows :
To evaluate the safet y and tolerability  of the E/C/F/TAF FDC in HIV -1 infected adults with 
ESRD on chronic HD at Week 96
To evaluate the 
proportion of subjects receiving E/C/F/TAF FDC achieving virologic 
respon se (HIV -1 RNA < 50 copies/mL , as defined by  the FDA snapshot analy sis) at 
Weeks 24, 48, and 96
To evaluate plasma pharmacokinetics (PK) of EVG, COBI, FTC, TAF ,and tenofovir ( TFV )
in HIV -1 infected patients with ESRD on chronic HD
To evaluate the safet y and tolerability  of bictegravir/emtricitabine/tenofovir alafenamide
(B/F/TAF )FDC in HIV -1 infected adults with ESRD on chronic HD in the open- label 
extension phase
1.2. Study Design
Design Configuration and Subject Population
GS-US-292-1825 is an open -label, multicenter, single -arm study  to assess the safet y, tolerability , 
PK, and efficacy  of the E/C/F/TAF FDC dosed once dail y in HIV -infected adult subjects with 
ESRD on chronic HD . 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 8 02 December 2019All subjects will switch from their current antiretroviral (A RV) regimen to E/C/F/TAF on Day 1. 
The treatment duration for E/C/F/TAF will be at least 96 weeks. 
After Week 96, subjects in the US will continue to take their stud y drug and attend visits every 
12 weeks until the End of E/C/F/TAF visit. At Week 96 or the End of E/C/F/TAF Visit, subjects 
will discontinue E/C/F/TAF FDC and be given the option to receive open -
label (OL) B/F/TAF 
FDC. All subjects participating in the OL extension of B/F/TAF FDC will return for study  visits 
at B/F/TAF Week 4 OL, Week 12 OL, and every  12 weeks thereafter for at least 48 weeks.
Subjects who do not wish to participate in the B/F/TAF OL extension phase will discontinue 
study  drug at Week 96.
Approximately  50 subjects with ESRD on chronic HD will be enrolled.
Treat ment Groups
All enrolled subjects will receive the following treatment:
FDC of e lvitegravir 150mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 
10mg administered orally , once dail y with food until the next hemodialy sis.On the day  of 
hemodialy sis, study  drug should be administered after completion of hemodialy sis.
Subjects who enroll into the B/F/TAF OL extension phase will receive the following treatment:
FDC of bictegravir 50 mg /emtricitabine 200 mg/tenofovir alafenamide 25 mg administered 
orally , once dail y with out regard to food until the next hemodialy sis.On the day  of 
hemodialy sis, study  drug should be administered after completion of hemodialy sis.
Key Eligibility Criteria 
HIV-infected adults who meet the following criteria:
No documented history  of HIV -1 resistance to EVG, FTC, lamivudine (3TC),or TFV
Currently  receiving a stable ARV regimen for ≥ 6 consecutive months prior to screening
Plasma HIV -1 RNA < 50 copies/mL  for at least 6 months preceding the screening visit
CD4 cell count of ≥ 200 cells/ μL
ESRD with eGFR < 15 mL /min by  Cockcroft- Gault (CG)
On chronic HD for ≥ 6 months prior to screening
Hepatitis C virus (HCV) infection allowed
Hepatitis B virus (HBV) infection not allowed
Genvoya/B iktarvy 
GS-US-292-1825 
Statistical Analysis Plan 
Studv Periods / Phases Version I 
The study w ill cons ist of a 30-day scree ning period (within 30 days before Day 1 vis it), followed 
by a 96-week EiC/FIT AF treatment period. 
After Week 96, all subjects partic ipating in the B/F/f AF OL extension phase will receive 
B/F/f AF FDC for at least 48 weeks . 
End of the study will occur when the last subject enro lled in the study has comp leted their 
last observation ( or visit). 
After a subject has comp leted/tenninated their partici pation in the study, long-tenn care of the 
subject will rema in the respons ibility of their primary treat ing physic ian. 
Schedule of Assessments {E/C/Fff AF Phase) 
Following Screening, eligible subjects will be required to return for study visits at Day 1 and 
Weeks 2, 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96. After the Week 96 visit, subjects who are not 
pla1ming to partic ipate in the B/F ff AF OL extens ion phase will stop study drug and complete a 
30-day Follow-up visit to complete their partic ipation in the study . Subjects who plan to 
partici pate in the B/F/TAF OL extension phase will continue to take E/C/F/f AF and attend visits 
every 12 weeks until the End of E/C/F/ TAF visit. 
For all subjects, HBV and HCV serologies will be analyzed at Screening . Adverse events (AEs), 
concom itant medication s, complete or symptom-dir ected phys ical examination s, laboratory 
analyses (hematolo gy and chem istry), HIV-1 RNA , and CD4 cell count will be assessed at 
Screen ing, Day 1, and all subsequent study visi ts. eGFR will be assessed at Screen ing, Day 1, 
and all subsequent study visi ts except the 30-day Follow-up visit. Fasting lipids and glucose will 
be assessed at Day 1 and every 24 weeks thereafter m1til Week 96 or End of E/C/F/f AF visit. 
Predose whole blood draw for plasma and periphera l blood mononucl ear cell (PBMC ) samples 
will be collected from all subjects at Week 4 or Week 12, which must be the day of hemodial ysis. 
Schedule of Assessments {B/Fff AF OL Extension Phase) 
All subjects partici pating in the B/F/f AF OL extension phase will return for study visits at 
B/F/fAF Week 4 OL, Week 12 OL, and every 12 weeks thereafter for at least 48 weeks . 
Adverse events, concom itant medications, comp lete or symptom-dir ected phys ical examination s, 
laboratory analyses (hematolo gy and chem istry), HIV-1 RNA , and CD4 cell count will be 
assessed at each visit. eGFR will be assessed at each visit except the 30-day Follow-up visit. 
Fasting lipids and glucose will be assessed every 24 weeks . 
CONFI DENT IAL Page 9 02 December 2019 
Genvoy a/B iktarvy 
GS-US-292-1825 
Statistical Analysis Plan 
Site and Stratum Enrollment Limits 
Approx imately 25 study sites in North America and Europe will partic ipate. There is no 
enrollment limit for individual sites. 
1.3. Sample Size and Power Version I 
A sample size of approx imately 50 subjects is based on pract ical considerat ions and is 
considered to be sufficient to evaluate the primary object ive of this study . The primary endpo int 
is the incidence of treatment-emergent Grade 3 or higher AEs up to Week 48. The Grade 3 or 
higher AE rate in Study GS-US-292-0112 in subjects that had mild to moderate renal impainnent 
was 8.8% at Week 48 for the E/C/F/ TAF ann. Therefore, with 50 subjects, and an assumed rate 
of Grade 3 or higher AEs being 10%, this study would prov ide 95% confidence for the primary 
endpo int to be within (1.7%, 18.3%) assum ing nonna l approximat ion to binom ial proportions . 
CONFI DENT IAL Page 10 02 December 2019 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 11 02 December 20192. TYPE OF PLANNED ANAL YSIS
2.1. Data Monitoring Committee Analyses
The Week 12 Independent Data Monitoring Committee (IDMC) anal ysis wasconducted after the 
first 25 subjects enrolled completed their Week 12 visit of the study  or prematurely  discontinued 
the study  drug. 
The IDMC’s role and responsibilities and the scope of analy sis provided to the 
IDMC were provided in a mutually  agreed upon charter, which defines the IDMC membership, 
meeting logistics, and meeting frequency .
2.2. Week 24 Analysis
AWeek 24 analysis wasconducted after all subjects enrolled either complete dtheir Week 24
visit of the study  or prematurel y discontinue dstudy  drug.
2.3. Week 48 Analysis
A Week 48 anal ysis wasconducted after all subjects enrolled either complete dtheirWeek 48 
visit of the study  or prematurel y discontinue dstudy  drug.
2.4. Week 96 Analysis
A Week 96 analysis wasconducted after all subjects enrolled either complete dtheir Week 96
visit of the study  or prematurel y discontinue dfrom the study .
2.5. Final Analysis
The fin
al statistical anal ysis will be conducted after all subjects either complete the study or 
prematurel y discontinue from the study. 
This SAP describes the analy sis plan for the final anal ysis.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 12 02 December 20193. GENERAL  CONSIDERA TIONS FOR DA TA ANAL YSES
The final analysis will include all data collected from the E/C/F/TAF and the B/F/TAF OL 
extension phases of the study . Separate tables and figu res will be created for each phase unless 
otherwise specified . Data collected from both phases will be included in data l istings. Data 
included in each phase are defined as follows:
E/C/F/TAF Phase Data
For subjects who are never treated in the B/F/TAF OL  extension phase of the study , all 
available data are considered as the 
E/C/F/TAF phase data. 
For subjects treated in the B/F/TAF OL extension phase of the stud y, E/C/F/TAF phase data 
are defined as data collected up to the B/F/TAF OL extension phase first dose date except for 
data on adverse events (AEs), concomitant medications, pregnancy , and death. For AEs, 
concomitant m edications, pregnancy , and death, only  data collected prior to the B/F/TAF 
OL extension phase first dose date are included. 
B/F/TAF OL Extension Phase Data 
B/F/TAF OL e xtension phase data are onl y available from subjects who enter the B/F/TAF 
OL extensio n phase of the study. B/F/TAF OL e xtension phase data are defined as data 
collected after the B/F/TAF OL extension phase first dose date except for data on AEs, 
concomitant medications, pregnancy, and death. For AEs, concomitant medications, 
pregnancy , and death, data collected on or after the extension phase first dose date are 
included. 
Analy sis results will be presented using descriptive statistics. For categorical variables, the 
number and percentage of subjects in each category  will be presented; for continuous variables, 
the number of subjects (n), mean, standard deviation (SD) or sta ndard error (SE), median, 
firstquartile (Q1), third quartile (Q3), minimum, and maximum will be presented.
By-subject listings will be presented for all subjects in the All Enrolled Subjects Analysis Set
unless otherwise specified, and sorted b y subject ID number, visit date, and time (if applicable). 
Data collected on log forms, such as AEs, will be presented in chronological order within a 
subject. 
In general, age (in y ears) on the date of the first dose of E/C/F/TAF study  drug will be used for 
analyses and presentation in listings. For screen failures, age on the date the informed consent 
was signed will be used. If only  birth y ear is collected on the eCRF, “01 January ” will be used 
for the unknown birth day and month for the purpose of age calculation ;similarly , if onl y birth 
year and month are collected on the eCRF, “01” will be used for the unknown birth day for the 
purpose of age calculation. 
In general, permanent discontinuation of study  drug refers to premature discontinuation of study  
drug or completion of study  drug.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 13 02 December 20193.1. Analysis Sets
Analy sis sets define the subject s to be included in an anal ysis.Anal ysis sets and their definitions 
are provided in this section. Subjects included in each anal ysis set will be determined before data 
finalization and will be identified in a subtitle of each table, figure, and listing. A summary  of the 
number and percentage of subjects in each anal ysis set will be provided. 
3.1.1. All Enroll ed Subjects Analysis Set
The All Enrolled Subjects 
Analysis Setwill include all subjects who are enrolled into th e study .
This is the primary  anal ysis set for by -subject listings.
3.1.2. B/F/TAF Enrolled Subjects Analysis Set
The B/F/TAF Enrolled Subjects Analysis Set will include all subjects who enrolled into the 
B/F/TAF OL extension phase of the st udy. This is the anal ysis set for b y-subject listings that 
pertain to the B/F/TAF OL extension phase onl y .
3.1.3. E/C/F/TAF Full Analysis Set
The E/C/F/TAF FullAnalysis Set(FAS )will includ e all subjects who (1) were enrolled in the 
study  and (2)received at leas t 1dose of E/C/F/TAF study  drug .This is the primary  anal ysis set 
for the E/C/F/TAF efficacy  analyses.
3.1.4. B/F/TAF Full Analysis Set
The B/F/TAF Full Analysis Set (FAS) will include all subjects who (1) were enrolled in the 
study  and (2)received at least 1 dose of B/F/TAF study  drug. This is the primary  anal ysis set for 
theB/F/TAF efficacy  analy ses.
3.1.5. E/C/F/TAF Safety Analysis Set
TheE/C/F/TAF Safety Analysis 
Setwill include all subjects who received at least 1 dose of 
E/C/F/TAF study  drug. This is the primary  anal ysis set for the E/C/F/TAF safet y analyses.
3.1.6. B/F/TAF Safety Analysis Set
TheB/F/TAF Safety Analysis S etwill include all subjects who received at least 1 dose of 
B/F/TAF study  drug. This is the primary  anal ysis set for the B/F/TAF safety  analy ses.
3.1.7. B/F/TAF Plasma PK Analysis Set
The B/F/TAF Plasma P K Analysis Set will include all subjects who (1) were enrolled into the 
study , (2) received at least 1 dose of B /F/TAF study  drug , and (3) have at least 1 nonmissing 
plasma PK concentration value for an y anal yte of interest reported by  the PK lab. The B/F/TAF 
Plasma PK A nalysis Set will be used for general B/F/TAF plasma PK analy ses.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 14 02 December 20193.2. Subject Grouping
For all analy ses, subjects will be grouped by  treatment received. All subjects received 
E/C/F/TAF. Subjects who enrolled into the B/F/TAF OL extension phase also received B/F/TAF. 
Subjects will be grouped under “GEN ”
for the E/C/F/TAF phase and under “ GEN to OL 
B/F/TAF ”for the B/F/TAF OL extension phase. In the subject listings, subjects who received 
only E/C/F/TAF will have treatment group of “GEN” and subjects who received E/C/F/TA F and 
OL B/F/TAF will have treatment group of “GEN toOL B/F/TAF”.
3.3. Strata and Covariates
This study  didnot use a stratified randomization schedule when enrolling subjects. No covariate s 
will be included in efficacy  or safety analyses.
3.4. Examination of 
Subject Sub group s
No subgroup anal yses are planned.
3.5. Multiple Comparisons
Adjustments for multiplicity  will not be made, because no formal statistical testing will be 
performed in this study .
3.6. Missing Data and Outliers
3.6.1. Missing Data
A missing dat umfor a give n study  analysis window may be due to any  of the following reasons:
A visit occurr ingin the window but data were not collected or were unusable
A visit not occur ringin the window
A subject permanently  discontinu ingfrom the s tudy before reaching the wind ow
In general, values for m issing data will not be imputed, unless methods f orhandling missing data 
are specified.
For missing last dos edate of study  drug, imputation rules are described in Section 3.8.1. The 
handling of missing orincomplete dates for AE onset is described in Section 8.3.5.2, and for 
concomitant medication in Section 8.6.2.
3.6.2.
Outliers
Outliers will be identified during the data management and data anal ysisprocess, but no 
sensitivity  anal yses will be done to evaluate the impact of outliers on efficacy  or safet y 
outcomes, unless specified otherwise . All data will be included in the analy ses.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 15 02 December 20193.7. Data Handling Conventions and Transformations
Laboratory  data that are conti nuous in nature but less than the lower limit of quantitation 
(LLOQ) or above the upper limit of quantitation will be imputed as follows:
A value that is 1unit less than the limit of quanti tation will be used for calculation of 
descriptive statistics if the datum is reported in the form of “ x”(where x is considered the 
limit of quantitation) . For example, if the values a re reported as < 50 and < 5.0, values of 49 
and 4.9, respectivel y,will be used for calculation of summary  statistics. An exception to this 
rule is an y value reported as < 1 or < 0.1, etc. For values reported as < 1 or < 0.1, a value of 
0.9 or 0.09, respectively , will be used for calculation of summary  statistics. 
A value that is 1unit above the limit of quantitation will be used for calculation of 
descriptive statistics if the datum is reported in the form of “> x” (where x is considered the 
limit of quantitation). Values with decimal points will follow the same logic as above.
The limit of quantitation will be used for calculation of desc riptive statistics if the datum is 
reported in the form of “ ≤ x” or “ x” (where x is considered the limit of quantitation).
Logarithm (base 10) transformation will be applied to HIV-1 RNA data for efficacy  anal yses. 
HIV
-1 RNA results of “No HIV- 1 RNA detected” and “< 20 c opies /mL HIV -1 RNA detected ” 
will be imputed as 19 copies/mL  for anal ysis purpose s.
3.8. Analysis Windows
3.8.1. Definition of Study Day
Study Day 1 is defined as the day when the first dose of E/C/F/TAF study  drug was taken, as 
recorded on the Study  Drug Administration eCRF form.
B/F/TAF Study Day 1 is defined as the day  when the first dose of B/F/TAF study  drug was 
taken, as recorded on the Study  Drug Administration eCRF form.
Study Days are calculated relative to Study  Day  1and B/F/TAF Stud y Da y 1. For events that 
occurred on or after Study Day 1, study  days are calculated as (visit date minus Study  Day 1 
plus 1). For events that occurred prior to Study Day 1, stud y days are calculated as (visit date 
minus Study  Day  1).
E/C/F/TAF Last Dose Date is the latest of E/C/F/TAF study  drug end dates recorded on the 
Study  Drug Administration eCRF form with “Permanently  Withdrawn” box checked for subjects 
who prematurely  discontinued study  drug or who completed study  drug according to the Study  
Drug Completion eCRF. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 16 02 December 2019If the date of E/C/F/TAF last dose is missing (eg, only year of last dose is know nor completel y 
missing due to lost to follow -up) for subjects who prematurel y discontinued or complete d study  
drug,the latest of the E/C/F/TAF study  drug start dates and end dates, the clinic visit dates, and 
the laboratory  visit dates ,excluding the date of the 30-day follow -up visit and any  dates on or 
after the first dose of B/F/TAF if applicable ,will be used to impute the last dose date
.For other 
partial missing last dose dates, please see programming specifications ( Appendix 7)for 
imputation rule details. 
B/F/TAF Last Dose Date is the latest of B/F/TAF study  drug end dates recorded on the Study  
Drug Administration eCRF form with “Permanently  Withdrawn” box checked for subjects who 
prematurel y discontinued study  drug or who completed study  drug according to the Study  Drug 
Completion eCRF. 
If the date of B/F/TAF last dose is missing (eg, only  year of last dose is known or completel y 
missing due to lost to follow -up) for subjects who prematurel y discontinued or completed stud y 
drug, the latest of the B/F/TAF s tudy drug start dates and end dates, the clinic visit dates, and the 
laboratory  visit dates ,excluding the date of the 
30-day follow -up visit and any  dates before the 
first dose of B/F/TAF , will be used to impute the last dose date. For other partial missi ng last 
dose date s, please see programming specifications ( Appendix 7)for imputation rule detail s. 
Last Study Date is the latest of E/C/F/TAF or B/F/TAF study  drug s tart date and end date, clinic 
visit dates, and laboratory visit dates, includ ing the 30- day follow -up visit date , for subjects who 
prematurel y discontinued the study  or who completed the study  according to Study  Completion 
eCRF.
Baseline value for the E/C/F/TAF phase is defined as the last value obtained on or prior to Study  
Day 1 for all assessment s. Baseline value for the B/F/TAF OL extension phase is defined as the 
last value obtained on or prior to B/F/TAF Study  Day 1 for all assessments. 
3.8.2.
Analysis Windows
Subject visits might not o ccur on protocol -specified day s. Therefore, for the purpose sof analy sis, 
observations will be assigned to anal ysis windows.
3.8.2.1. Analy sis Windows for E/C/F/TAF Phase
The anal ysis windows for HIV- 1 RNA, CD4 cell count, CD4%, hematology (excluding INR) ,
chemistry , eGFR CG, vital signs, weight, visual a nalogue s cale ( VAS ), and healthcare utilization 
assessment are presented in 
Table 3-1.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 17 02 December 2019Table 3-1. A nalysis W indows for HIV -1 RNA, CD4 Cell C ount, CD4%, 
Hematologya, Chemistryb,eGFR CG, Vital Signs, Weight, Visual 
Analogue Scale (VAS), and Healthcare Utilization Assessment
(E/C/F/TAF Phase )
Visit ID Nom inal Day Lower Limit Upper Limit
Baseline 1
Week 2 14 2 21
Week 4 28 22 42
Week 8 56 43 70
Week 12 84 71 126
Week 24 168 127 210
Week 36 252 211 294
Week 48 336 295 378
Week 60 420 379 462
Week 72 504 463 546
Week 84 588 547 630
Week 96 672 631 714
Week 108 756 715 798
Week 120 840 799 882
a Hematology p anel excluding INR and prothrombin time .
b Chemistry profile includes alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, 
albumin, LDH, CPK, bicarb onate, BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, 
uric acid, and amylase. 
Note: The above analysis windows will also be use d for bone biomarker of parathyroid hormone (PTH) . 
The anal ysis windows for fasting glucose andlipid panel (total cholesterol, HDL, direct LDL, 
triglycerides , and total cholesterol to HDL ratio ) are presented in Table 3-2.
Table 3-2. Analysis Windows forFasting Glucose andLipid Panel (E/C/F/TAF
Phase )
Visit ID Nom inal Day Lower Limit Upper Limit
Baseline 1
Week 24 168 2 252
Week 48 336 253 420
Week 72 504 421 588
Week 96 672 589 756
Week 120 840 757 924
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 18 02 December 2019The anal ysis windows for prothrombin time and INR are presented in Table 3-3. 
Table 3-3. Analysis Windows for prothrombin time and INR (E/C/F/TAF Phase )
Visit ID Nom inal Day Lower Limit Upper Limit
Baseline 1
Week 24 168 2 252
Week 48 336 253 588
Week 120 840 589 1092
The anal ysis windows for SF -36 and HIV -TSQc are presented in Table 3-4. 
Table 3-4. Analysis Windows for SF- 36and HIV -TSQc (E/C/F/TAF Phase )
Visit ID Nom inal Day Lower Limit Upper Limit
Baselinea1
Week 24 168 2 252
Week 48 336 253 420
Week 72 504 421 588
Week 96 672 589 756
Week 120 840 757 924
a HIV TSQc does not have a baseline assessment so analysis wind ow at baseline does not apply. 
The anal ysis windows for HIV- TSQs are presented in Table 3-5. 
Table 3-5. Analysis Windows for HIV -TSQs (E/C/F/TAF Phase )
Visit ID Nom inal Day Lower Limit Upper Limit
Baseline 1
Week 4 28 2 98
Week 24 168 99 252
Week 48 336 253 420
Week 72 504 421 588
Week 96 672 589 756
Week 120 840 757 924
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 19 02 December 2019The anal ysis windows for safet y ECG are presented in Table 3-6.
Table 3-6. Analysis Windows for Safety ECG (E/C/F/TAF Phase )
Visit ID Nominal Day Low er Lim it Upper Limit
Baseline 1
Week 48 336 2 504
Week 96 672 505 840
3.8.2.2. Analy sis Windows for B/F/TAF OL Extension Phase
The anal ysis windows for HIV- 1 RNA, CD4 cell count, CD4%, hematology , chemistry , 
eGFR CG, vital signs, and weight are presented in Table 3-7.
Table 3-7. Analysis Windows for HIV -1 RNA, CD4 Cell Count, CD4%,
Hematologya, Chemistryb, eGFR CG, Vital Signs, and Weight (B/F/TAF
OL Extension Phase )
Visit ID Nom inal Day Lower Limit Upper Limit
Baseline 1
Week 4 28 2 56
Week 12 84 57 126
Week 24 168 127 210
Week 36 252 211 294
Week 48 336 295 378
Week 60 420 379 462
a Hematology panel including PT/INR.
b Chemistry profile includes alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, 
albumin, LDH, CPK, bicarbonate, BUN, calcium, chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, 
uric acid, and amylase. 
Note: The above analysis windows will also be used for bone biomarker of parathyroid hormone (PTH).
The anal ysis windows for fasting glucose andlipid panel (total cholesterol, HDL, direct LDL, 
triglycerides , and total cholesterol to HDL ra tio) are presented in Table 3-8.
Table 3-8. Analysis Windows for Fasting Glucose and Lipid Panel (B/F/TAF OL 
Extension Phase )
Visit ID Nom inal Day Lower Limit Upper Limit
Baseline 1
Week 24 168 2 252
Week 48 336 253 420
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 20 02 December 2019The anal ysis windows for SF-36 and HIV -TSQ are presented in Table 3-9.
Table 3-9. Analysis Windows for SF -36 and HIV -TSQ (B/F/TAF OL Extension
Phase)
Visit ID Nominal Day Low er Lim it Upper Limit
Baseline 1
Week 4 28 2 98
Week 24 168 99 252
Week 48 336 253 420
The anal ysis windows for safet y ECG are presented in Table 3-10.
Table 3-10. Analysis Windows for Safety ECG (B/F/TAF OL Extension Phase )
Visit ID Nominal Day Low er Lim it Upper Limit
Baseline 1
Week 48 336 2 504
3.8.3. Selection of Data in the Event of Multiple Records in a Window
Depending on the statistical anal ysis method, single values may  be required for each analy sis 
window. For example, change from baseline b y visit usually  requires a single value, whereas a 
time-to-event anal ysis would not require 1value per anal ysis window. When a single value is 
needed, the following rule(s) will be used.
If multiple nonmissing numeric observations exist in a window, records will be chosen as follows:
For baselin e, the latest available record on or prior to the first dose of E/C/F/TAF or 
B/F/TAF stud y drug, as appropriate, will be selected. If there are multiple records with the 
same time or no time recorded on the same day , average will be used for the baseline value , 
except for HIV -1 RNA (see below) . 
For post baseline visits : 
For CD4 cell count and CD4%, the record(s) collected on the latest day in the window 
will be selected for anal ysis.
For other numeric observations (except HIV -1 RNA) , the record (s) collect ed on the day
closest to the nominal day for that visit will be selected. If there are 2 records equidistant 
from the nominal day , the lat erday 
will be selected.
For an y numeric observations except HI V-1 RNA, i f there aremultiple records on the 
selected day , the average will be taken.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 21 02 December 2019For baseline and postbaseline HIV -1 RNA, the latest (considering both date and time) 
record(s) in the window will be selected. If both “HIV RNA Taqman 2.0” and “HIV RNA 
Repeat” (ie, the HIV -1 RNA result obtained from an additional aliquot of the original sample) 
are available with the same collection time, the results from the “HIV RNA Repeat” will be 
selected for analy sis purposes; otherwise, if the re are multiple “HIV RNA Taqman 2.0” 
records with the same collection tim e, the geometric mean will b e taken for analy sis purposes.
If multiple valid nonmissing categorical observations exist in a window, records will be chosen 
as follows:
For baseline, the last available record on or prior to the first dose of E/C/F/TAF or B/F /TAF 
study  drug, as appropriate, will be selected . If there are multiple records with the same time 
or no time recorded on the same day , the value with the lowest severit y will be selected 
(eg,normal will be selected over abnormal for safety  ECG findings ).
For post baseline visits, the most conservative value within the window will be selected for 
categorical observations other than patient reported outcomes (eg,abnormal will be selected 
over normal for safety  ECG findings ).
For patient -reported outcomes collected at postbaseline visits, the record closest to the 
nominal day  for that visit will be selected. If there are 2 records equidistant from the nominal 
day, the late rwill be selected.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 22 02 December 20194. SUBJECT DISPOSITION
4.1. Subject Enrollment and Disposition
4.1.1. Subject En rollment
The number and percentage of subjects enrolled foreach country  and investigator will be 
summarized using theE/C/F/TAF S afety  Analysis Setand the B/F/TAF Safety  Anal ysis Set .The 
denominator for these summaries will be the number of subjects in th erespective S afety 
Analysis Set.
A list ingof subject enrollment including date of informed consent signed and met all eligibility  
criteri a will be provided (see Appendix Listing 1). 
4.1.2. Subject Disposition
Asummary  of subject disposition will be provided (see Appendix Table 1). This summary  will 
include the number of subjects screened, screen failure subjects who were not enrolled, subjects 
who met all eligibility  criteria and were not enrolled, subjects enroll ed,subjects enroll ed but not 
treated, subjects in the E/C/F/TAF 
Safety  Analysis Set,subjects in the B/F/TAF Safety  Anal ysis 
Set, subjects in the E/C/F/TAF FAS, and subjects in theB/F/TAF FAS.
In addition, the number and percentage of subjects in the following categories will be 
summarized:
Completed E/C/F/TAF study  treatment
Prematurel y discontinued E/C/F/TAF study  treatment (with summary  of reasons for 
discontinuing study  drug )
Enrolled in the B/F/TAF OL extension phase of the study
Completed B/F/TAF OL study  treatment
Prematurel y discontinu edB/F/TAF OL study  treatment (with summary  of reasons for 
discontinuing study  drug )
Completed the study
Prematurel y discontinu edfrom the study  (with summary  of reasons for discontinuing study ) 
The denominator for the percentages of subjects in each category, except for the categories of 
“completed B/F/TAF OL study  treatment ”and “ prematurel y discontinu edB/F/TAF OL study  
treatment ”
, will be the number of subjects in the E/C/F/TAF S afety Analysis Set. The 
denominator for the percentage of subjects in the categories of “completed B/F/TAF OLstudy  
treatment ”and “prematurely  discontinu edB/F/TAF OL study  treatment ” will be the number of 
subjects in the B/F/TAF Safety  Anal ysis Set.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 23 02 December 2019No inferential statistics will be generated. D ata listing sof reasons for premature study  drug
discontinuation and premature study  discontinuation will be provided.
4.2. Extent of Study Drug Exposure and Adherence
4.2.1. Duration of Exposure to E/C/F/TAF Study Drug
Duration of exposure to E/C/F/TAF study  drug will be defined as ( the last E/C/F/TAF dose date 
Study  Day  1 +1), regardless of temporary  interruptions in study  drug administration, and will 
be expressed in weeks using up to 1 decimal place ( eg, 4.5 weeks). 
Duration of exposure to E/C/F/TAF study  drug will be summarized using descriptive statistics 
(n, mean, SD, median, Q1, Q3, minimum ,and maximum) and as the number and percentage of 
subjects exposed for specified periods , ie, ≥ 2 weeks (14days), ≥ 4 weeks (28 days), ≥ 8 weeks
(56days), ≥12 weeks (84 day s), ≥24 weeks (168 days), ≥ 36 weeks (252 days),≥ 48 weeks 
(336 day s), ≥60 weeks (420 days), ≥72 weeks (504 days), ≥84 weeks ( 588days), ≥ 96 weeks 
(672 days), ≥108 weeks (756 days ), etc.
Summari es will be provided for subjects in the E/C/F/TAF Safety  AnalysisSet. No inferential 
statistics will be provided.
Time to premature discontinuation of E/C/F/TAF study  drug will be anal yzed using the 
Kaplan -Meier (KM) method based on the E/C/F/TAF Safety  Analysis Set. Subjects who 
completed E/C/F/TAF 
study  treatment will be censored on the last E/C/F/TAF dose date. A plot 
of KM estimates for time to premature discontinuation of E/C/F/TAF study  drug will be 
generated. 
4.2.2. Duration of Exposure to B/F/TAF Study Drug
Duration of exposure to B/F/TAF study  drug will be defined as (the last B/F/TAF dose date 
B/F/TAF Study  Day  1 +1), regardless of temporary  interruptions in study  drug administration, 
and will be expressed in weeks using up to 1 decimal place (eg, 4.5 weeks). 
Durat ion of exposure to B/F/TAF study  drug will be summarized using descriptive statistics 
(n,mean, SD, median, Q1, Q3, minimum, and maximum) and as the number and percentage of 
subjects exposed for specified periods, ie, ≥ 2 weeks (14days), ≥ 4 weeks (28 days), ≥ 8weeks 
(56days), ≥ 12 weeks (84 day s), ≥ 24 weeks (168 days), ≥ 36 weeks (252 days),and ≥ 48 weeks 
(336 day s).
Summaries will be provided for subjects in the B/F/TAF Safet y Anal ysisSet. No inferential 
statistics will be provided.
4.2.3. Adherence with Study Drug
Study  drug adherence will be computed based on pill counts. The numbers of pills of study  drug 
dispensed and returned are captured on the Study  Drug A ccountability  eCR F. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 24 02 December 2019Adherence (%) to E/C/F/TAF study  drug will be calculated as follows:
prescribed pillsofNo. Total taken pillsofNo. Total100 (%) Adherence  
period dispensing eachat prescribed pillsofNo.period dispensing eachat  takenpillsofNo.100[2][1]

[1] Number of pills taken at a distinct dispensing period for a study drug is calculated as the minimum of (a)the daily number 
of pills prescribed for the study drug multiplied by the duration of treatment at the dispensing period, and (b)the n umber of 
pills take n for the study drug (number of pills dispensed minus the number of pills returned). Total number of pills taken is 
determined by summing the number of pills taken from all evaluable dispe nsing periods.
[2] Number of pills prescribed at a distinct dispensing period for a study drug is calculated as the daily number of pills 
prescribed for the study drug multiplied by the duration of treatment at the dispensing period. Total number of pills 
prescribed is determined by summing the number of pills prescribed from all evaluable dispensing periods.
The duration of treatment at each dispensing period is calculated as the minimum of ( a)the 
lastreturned date of study  drug at a dispensing period, (b)date of premature discontinuation of 
the study  drug, and (c) next pill dispensing date of the study  drug, minus dispensing date of the 
study  drug . 
The next pill dispensing date is the following dispensing date of the stud y drug regardless of the 
bottle return date.
For a record where the number of pills returned was missin g (with “Yes” answered for 
“Was Bottle returned?” question), it is assumed the number of pills returned was zero. If the 
number of pills dispensed was missing or an y study  drug bottle was not returned, or the bottle 
return status was unknown, then all records in that dispensing period will be excluded from both 
denomi nator and numerator calculation.
Adherence will be calculated using all data from the entire dosing period up to the date of 
permanent discontinuation of the E/C/F/TAF study  drug forsubjects who prematurel y 
discontinued study  drug or completed E/C/F/TAF study  drug . 
Descriptive statistics (n, mean, SD, median, Q1, Q3, minimum ,and maxi mum) along with the 
number and percentage of subjects belonging to adherence categories ( ie, < 80%, 
≥80% to 
<90%, 90% to < 95%, 95%) will be provided for subjects who return at least 1 bottle and 
have calculable adherence during the study  in the E/C/F/TAF 
Safet y Analysis Set. No inferential 
statistics will be provided.
Adherence will be calculated in a similar manner for the B/F/TAF Safet y Analy sis Set.
4.3.
Protocol Deviations
Alisting will be pro vided for subjects in the All Enrolled Subjects anal ysissetwho violated at 
least 1 inclusion or exclusion criterion. The listing will include the criteria not met.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 25 02 December 20195. BASELINE CHARACTERIS TICS
5.1. Demographics and Baseline Characteristics
Subject demographic data (eg, age, sex at birth , race, and ethnicity ) and baseline characteristics 
(eg,body  weight, height, and body  mass index [BMI ]) will be summarized using descriptive 
statistics ( n, mean, SD, median, Q1, Q3, minimum ,and maximum) for continuous data and by  
the number and percentage of subjects for categorical data. The summaries of demographic data 
and baseline characteristics will be provided for the E/C/F/TAF 
Safet y Analysis Setand the 
B/F/TAF Safety  Anal ysis Set .Baseline for each phase is defined in Section 3.8.1.
5.2. Baseline Disease Characteristics
The following baseline disease characteristics collected at enrollment will be summarized:
Mode of infection (HIV risk factors)
HIV disease status at study  entry
HCV antibody  status at study  entry
Medical history  at study  entry : Type I or II diabetes (Yes/No), cardiovascular disease
(Yes/No), h yperten sion (Yes/No), and h yperlipidemia (Yes/No) (see Appendix 7for details) 
Smoking status at study  entry : (a) Never Smoked, (b) Former Smoker, and (c) Current 
Smoker (s ee Appendix 7for details)
Duration of hemodial ysis at study  entry  (years)
Pre-switch ARV categories: (a) Containing TDF, (b) Containing ABC, and (c) Containing 
Neithe r
Pre-
switch ARV categories: (a) Containing 3TC, (b) Containing ABC, (c) Containing TDF, 
(d)Containing FTC
Pre-switch ARV 3rdAgent Category : (a) INST I, (b) PI, (c)NNRTI, (d) CCR5 Antagonist
The following baseline disease characteristics collected prior to E/C/F/TAF administration and 
prior to B/F/TAF administration will be summarized for the E/C/F/TAF Safety  Anal ysis Set and 
the B/F/TAF Safety  Analy sis Set, respectivel y:
HIV-1 RNA categories (copies/mL ): (a) < 50 and(b) ≥ 50
CD4 cell count (/μL)
CD4 cell count categories (/μL): (a) < 50, (b) ≥ 50to< 200 , (c) ≥ 200 to < 350, 
(d)≥ 350 to< 500 , and (e) ≥ 500
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 26 02 December 2019CD4%
eGFR CG(mL/min)
No inferential statistics will be provided.
5.3. Medical History
Subjects’ answers to the following questions prespecified on th e Medical History  CRF will be 
listed: 
Does the Subject have diabetes? (Ty pe I or II)
Have an y first-degree relatives e xperienced MI or stroke before the age of 50?
In addition, subject s ’ kidney  transplant registration status collected b y the Tran splant History  
CRF will be listed. 
General medical history  data will be collected at screening and 
listed only. General m edical 
history  data will be coded using the current version of Medical Dictionary  for Regulatory  
Activities (MedDRA) .
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 27 02 December 20196. ANAL YSES OF  PRIMA RY ENDPOINT
6.1. Definition of the Primary Endpoint
The primary  endpoint of this study  is the incidence of treatment -emergent Grade 3 or higher AEs
in subjects receiving E/C/F/TAF up to Week 48.The anal ysis of the primary  endpoint was 
conducted for the Week 48 clinical study  report and will not be repeated for this final analysis.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 28 02 December 20197. EFFICACY  ANAL YSES
The proportion sof subjects with HIV -1 RNA < 50 copies/mL  at Weeks 24 and 48 as defined by  
the US FDA -defined snapshot algorithm were summari zed as part of the Week 48 clinical study 
report and will not be repeated for the final analysis. 
7.1. Efficacy Endpoints as Secondary Study Endpoints
Secondary  efficacy  endpoints for the final anal ysisinclude the following: 
The proportion of subjects with HI V-1 RNA < 50copies/mL  at Week 96as defined b y the 
US FDA -defined snapshot algorithm
The proportion of subjects with HI V-1 RNA < 50 copies/mL  by visit
The change from baseline in CD4 cell count and CD4% by visit
7.2. Analysis of Efficacy Endpoints
7.2.1.
Analysis of the Proportion of Subjects with HIV- 1 RNA < 50 copies/mL at 
Week 96 as Determined by US FDA -defined Snapshot Algorithm
US FDA -Defined Snapshot Algorithm
The anal ysis window at Week 96 is defined as from Study  Day  631 to Study  Day  714, inclusive.
All HIV -1 RNA data collected on -treatment ( ie, data collected up to 1 day after the last dose date 
of E/C/F/TAF 
study  drug) will be used in the US FDA -defined snapshot algorithm. Virologic 
outcome for Week 96 will be defined using the following categories:
HIV -1 RNA < 50 copies/mL : this includes subjects who have th e last available on -treatment 
HIV-1 R NA < 50 copies/mL  in the analy sis window
HIV
-1 RNA ≥ 50 copies/mL : this include ssubjects
1) Who have the last available on- treatment HIV -1 RNA ≥ 50 copies/mL  in the analysis 
window , or
2) Who do not have on- treatme nt HIV -1 RNA data in the analysis window and
a)Who discontinue study  drug prior to or 
in the analy sis window due to lack of efficacy , 
or
b)Who discontinue study drug prior to or in the analy sis window due to AE or death 
and have the last available on- treatment HIV -1 RNA ≥ 50 copies/mL , or
c)Who discontinue study  drug prior to or in the analy sis window due to reasons other 
than AE, death, or lack of efficacy and have the last available on
-treatment HIV-1 
RNA ≥ 50 copies/mL
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 29 02 December 2019No Virologic Data in Window : this inclu des subjects who do not have on -treatment HIV -1 
RNA da ta in the analysis window because of the following:
3)Discontinuation of study drug prior to or in the analy sis window due to AE or death an d 
the last available on -treatment HIV -1 RNA < 50copies/mL , or
4)Discontinuation of study  drug prior to or in the analy sis window due to reasons other than 
AE, death, or lack of efficacy  and the last available on -treatment HIV -1 RNA is 
< 50 copies/mL, or
5)Missing data during the window but on study  drug
The flowchart of the snapshot algorithm is provided in Appendix 3.
The number and percentage of subjects with HIV -1 RNA 
< 50 copies/mL, HIV- 1 RNA 
≥ 50 copies/mL , and reasons for no virologic data at Week 96 will be summarized using the 
E/C/F/TAF FAS . The 95% confidence intervals (CI s) for percentages of subjects with HIV -1 
RNA < 50 copies/mL and HIV- 1 RNA ≥ 50 copies/mL will be constructed using the Exact 
method (see Appendix Table 1Appendix Table 2). 
The same anal ysis will be repeated for proportion of subjects with HIV -1 RNA < 20copies/mL 
at Week 96 as defined b y US FDA -defined snapshot algorithm.
The Week 96 virologic outcomes for th
e US FDA -defined snapshot algorithm will be listed 
(seeAppendix Listing 2).
7.2.2. Analysis of Other Efficacy Endpoints
7.2.2.1. By-Visit Anal ysis of the Proportion 
of Subjects with HI V-1 RNA < 50copies/mL  
by Missing  Failure and Missing  Excluded Approaches
The proportion of subjects with HI V-1 RNA < 50 copies/mL  will be summarized using the 
following 2 methods for imputing missing HIV -1 RNA values: 
Missing  Fai lure (M  F) 
In this approach, all missing data will be treated as HIV- 1 RNA  50copies/mL . The 
denominator for percentages is the number of subjects in the E/C/F/TAF FAS.
Missing Excluded (M 
 E)
In this approach, all missing data will be excluded in the computation of the percentages 
(ie,missing data points will be excluded from both the numerator and denominator in the 
computation). The denominator for percentages at a visit is the number of subjects in the FAS 
with nonmissing HIV -1 RNA value at that visit.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 30 02 December 2019For both M  F and M E anal yses, thenumber and percentage of subjects with HIV -1 RNA in 
the following categories will be summarized (see Appendix Table 3):
< 50 copies/mL
< 20 copies/mL
■< 20 Not Detectable
■< 20 Detectable
20 to < 50 copies/mL  
≥ 50 copies/mL  
The 95% CIs of the proportion of subjects with HIV-1 RNA < 50 copies/mL will be provided 
using the Exact method.
Separate summaries will be provided for the E/C/F/TAF FAS and the B/F/TAF FAS.
7.2.2.2. Analy sis of CD4 Cell Count and CD4 %
Values and c hanges from baseline in CD4 cell count and CD4% will be summarized at each 
postbaseline visit using d escriptive statistics based on observ ed on -treatment values. On -treatment 
values include data collected after the first dose date up to the applicable lastdose date + 1 day for 
subjects who permanently discontinued the applicable study  drug.
In addition, values and change sfrom baseline in CD4 cell counts with missin g values imputed 
using the last observation carried forward (LOCF) method will be summarized at each 
postbas eline visit . The algorithm for LOCF is as follows:
If a value is missing in an anal ysis visit window, the missing value will be replaced with the 
last on- treatment value (ie, up to 1 day  after the last dose date of applicable study  drug) 
observed before the analysis visit window that has the missing value.
Baseline values will not be used for imputation; subjects who had no postbaseline CD4 
assessment will be excluded from the postbaseline summaries.
The mean and 95% CI and median (Q1, Q3) of values and change from baseline in CD4 cell 
count over time will be plotted using observed data.
Separate summaries will be provided for the E/C/F/TAF FAS and the B/F/TAF FAS.
7.3. Changes From Protocol -Specified Efficacy Analyses
There are no changes from the protocol-specified efficacy  anal yses.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 31 02 December 20198. SAFETY  ANAL YSES
Safety  data will be summarized for the subje cts in the E/C/F/TAF Safety  Analysis Setand the 
B/F/TAF Safe ty Anal ysis Set .All safety  data will be included in data listings.
The primary  endpoint of the incidence of treatment-emergent Grade 3 or higher AEs up to 
Week 48 was conducted for the Week 48 clinical study  report and will not be repeated for th is
final anal ysis.
The secondary  endpoint of the incidence of treatment-emergent Grade 3 or higher AEs up to 
Week 96 is defined in a similar manner to the primary  endpoint included in the Week 48 clinical 
study  report (See Section 8.1).
E/C/F/TAF Phase
For subjects who do not participate in the B/F/TAF OL extension phase, a ll safet y data collected
from the first dose of E/C/F/TAF up to 30days after permanent discontinuation of E/C/F/TAF 
study  drug will be summarized, unless specified otherwise. For subjects who participate in the 
B/F/TAF OL extension phase, a ll safety  data collected up to the date of the first B/F/TAF study  
drug dose will be summa rized, unless specified otherwise.
B/F/TAF OL Extension Phase
All safet y data collected from the first dose of B/F/TAF up to 30days after permanent 
discontinuation of B/F/TAF study  drug will be summarized, unless specified otherwise.
8.1. Adverse Events Up to Week 96
Adverse events up to Week 96, or adverse events on or prior to Week 96, refers to those adverse 
events with onset date (if applicable) on or prior to the date of the Week 96 visit, as recorded on 
the Visit Date CRF, for subjects who had the Week 9 6 visit performed according to the 
Visit Date CRF. 
If the onset date of an AE is partially  missing (with only  year and month or y ear alone), the event 
is considered on or prior to Week 96 if the month and y ear (or y ear alone) of the AE onset date is 
the same as or before the month and y ear (or year) of the Week 96 visit date recorded on the 
Visit Date CRF. 
If the onset date of an AE in completely missing, the event is considered on or prior t o the 
Week 96 if an y of the following three criteria are met: 
The AE stop date is on or prior to the Week 96 visit date; or
The AE stop date is partially  missing, with the month and y ear (or y ear alone) on or prior to 
the Week 96 visit date; or 
The AE st op date is completely  missing, including the case when AE is still ongoing. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 32 02 December 2019For subjects who prematurely  discontinued the study  prior to the Week 96 visit, all adverse 
events will be considered AEs on or prior to Week 96. 
8.2. Analysis of Adverse Events Up to Week 96
The number and percentage of subjects who experienced at least 1 Grade 3 or 4 
treatment -emergent AE will be provided by  system organ class (SOC) and preferred term (PT) 
using the E/C/F/TAF Safety  Anal ysis set. For those AEs that occurred more than once in an 
individual subject during the specified time frame, the most severe grade will be used.
Multiple events will be counted only  once per subject in the summaries. Adverse events will be 
summarized and listed first in alphabetical order of SOC, and then by  PT in descending order of 
total frequency  within each SOC. Grade 3 or 4 treatment- emergent AEs will also be summarized 
by PT onl y, in descending order of total frequency.
Grade 3 or 4 treatment -emergent study -drug related AEs by  Week 96 will be su mmarized by  
SOC and PT. 
The general safet y summaries described in Section 8.3will present all TEAEs (or subset of 
TEAEs) .
8.3. Adverse Events and Deaths
8.3.1. Adverse Event Dictionary
Clinical and laboratory  adverse events (AEs) will be coded using the current version of 
Medical Dictionary  for Regulatory  Activities (MedDRA). SOC , high -level group term (HLGT), 
high le vel term (HLT), PT , and low est-level term (LLT) will be provided in the AE dataset .
8.3.2. Adverse Event Severity
Adverse events are graded by  the investigator as Grade 1 (mild), Grade 2 (moderate), Grade 3 
(severe) ,or Grade 4 (life threatening) according to toxicity criteria specified in the study  
protocol. The seve rity grade of events for which the investigator did not record severity  will be 
leftas “missing” for data listings. 
8.3.3. Relationship of A dverse Events to Study Drug
Related AEs are those for which the investigator selected “Related” on the AE eCRF to the 
question of “Related to Study  Treatment”. Events for which the investigator did not record 
relationship to study  drug will be considered related to study  drug for summary  purpose s. 
However, b y-subject data listings will show the relationship as missing.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 33 02 December 20198.3.4. Serious A dverse Events
Serious adverse events (SAEs) will be identified and captured as SAEs if AEs mee t the 
definition of SAE specified in the study  protocol. Serious adverse events captured and stored in 
the clinical database will be reconciled with the SAE d atabase from the Gilead 
Pharmacovigilance & Epidemiology  Department before data finalization. 
8.3.5. Treatment -Emergent A dverse Events
8.3.5.1. Definition of Treatment- Emergent Adverse Events
E/C/F/TAF phase treatment- emergent AEs are defined as 1 or both of the following :
Any AEs with an onset date on or after the E/C/F/TAF study  drug start date and no later than 
30 day s after permanent discontinuation of the E/C/F/TAF study  drug for subjects who do 
not participate in the B/F/TAF OL extension phase or the day  prior tothe date of the first 
B/F/TAF study  drug dose for subjects who participate in the B/F/TAF OL extension phase , 
or
Any AEs leading to premature discontinuation of E/C/F/TAF study  drug.
B/F/TAF OL extension phase treatment -emergent AEs are defined as 1 or both of the fo llowing :
Any AEs with an onset date on or after the B/F/TAF study  drug start date and no later than 
30 day s after perma nent discontinuation of the B/ F/TAF stud y drug, or
Any AEs leading to premature discontinuation of B /F/TAF study  drug.
8.3.5.2. Incomplete Dates
If the onset date of the AE is incomplete and the AE stop date is not prior to the first dose date of 
E/C/F/TAF study  drug, then the month and y ear (or y ear alone if month is not recorded) of onset 
determine whether an AE is treatment eme rgent. 
The event is considered treatment emergent for the E/C/F/TAF phase if both of the following 2 
criteria are met: 
The month and y ear (or year) of the AE onset is the same as or after the month and y ear 
(oryear) of the first dos edate of E/C/F/TAF study  drug, and 
The month and y ear (or year) of the AE onset is the same as or before the month and y ear 
(oryear) of the date corresponding to the minimum of (1) the last dose of E/C/F/TAF study 
drug plus 30 day s AND (2) the first dose of B/F/TAF study  drug minus 1 day  
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 34 02 December 2019The event is considered treatment emergent for the B/F/TAF OL extension phase if both of the 
following 2 criteria are met: 
The month and y ear (or year) of the AE onset is after the month and year (or year) of the 
first dos edate of B/F/T AF study  drug, and
The month and y ear (or year) of the AE onset is the same as o r before the month and y ear 
(oryear) of the date corresponding to 30 day s after the date of last dose of B/F/TAF study  
drug
An AE with completel y missing onset and stop dates, or with the onset date missing and a stop 
date on or after the first dose date of E/C/F/TAF study  drug, wil l be considered to be treatment
emergent for the E/C/F/TAF phase . In addition, an AE with the onset date missing and 
incomplete stop date with the same or later month and y ear (or y ear alone if month is not 
recorded) as the first dos edate of E/C/F/TAF study  drug will be considered treatment emergent. 
8.3.6. Summaries of Adverse Events and Deaths
The number and percentage of subjects who experienced at least 1 TEAE will be provided and 
summarized by SOC, HLT, and PTseparatel y for the E/C/F/TAF Safet y Analysis Set and 
B/F/TAF Safety  Anal ysis Set . For other AEs described below, su mmaries will be provided by  
SOC and PT separatel y for the E/C/F/TAF Safety Analysis Setand B/F/TAF Safet y Anal ysis 
Set: 
Any Grade 2, 3, or 4 treatment- emergent AE
Any Grade 3 or 4 treatment -emergent AE
All treatment -emergent study -drug-related AEs
Any Grade 2, 3, or 4 treatment -emergent stud y-drug-related AE
Any Grade 3 or 4 treatm ent-emergent study -drug-related AE
All treatment -emergent SAEs
All treatment -emergent study -drug-related SAEs
All treatment -emergent AE s that caused premature discontinuation from study  drug
A brief, high- level summary  of AEs described above will be provided by  the number and 
percentage of subjects who experienced the above AEs. Treatment -emergent deaths observed in 
the study  will also be included in this summary . 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 35 02 December 2019For the E/C/F/TAF Safety Ana lysis Set summary , treatment -emergent death refers to a death that 
occurred between t he first E/C/F/TAF dose date and the last E/C/F/TAF dose date plus 30 day s 
(inclusive) for subjects who do not participate in the B/F/TAF OL extension phase or the day  
prior to the date of the first B/F/TAF study
 drug dose for subjects who participate in the 
B/F/TAF OLextension phase . 
For the B/F/TAF Safety  Analy sis Set summary , treatment -emergent death refers to a death that 
occurred between the first B/F/TAF dose date a nd the last B/F/TAF dose date plus 30 day s 
(inclusive). 
Multiple events will be counted only once per subject in each summary . Adverse events will be 
summarized and listed first in alphabetical order of SOC and HL
T within each SOC 
(ifapplicable), and the n by PT in descending order of total frequency  within each SOC. For 
summaries by  severit y grade, the most sever egrade will be used for those AEs that occurred 
more than once in an individual subject during the study . 
In addition to the above summary  tables, all treatment- emergent AEs will be summarized by  PT 
only, in descending order of total frequency . 
In addition, data listings will be provided for the following: 
All AEs (with a variable indicating whether the event is treatment -emergent)
Grade 3 and 
4 AEs
Study -drug-related AEs
SAEs
Study -drug-related SAEs
Deaths report ed
AEs leading to premature discontinuation of study drug.
8.3.7. Additional Analysis of Adverse Events
8.3.7.1. Stage 3 Opportunistic I llnesses in HIV
On an ongoing basis, AEs will be reviewed for events that might meet the definition of stage 3 
opportunistic illnesses in HIV that are indicative of an AIDS -defining d iagnos is (see Protocol 
Appendix 8). The Gilead medical monitor will review the possible stage 3 opportunistic illnesses
and approve the events that meet the definition. Events that meet the stage 3 opportunistic 
illnesses definition diagnosis will be listed for all enrolled subjects. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 36 02 December 20198.3.7.2. Common Adverse Eve nts Included in the FTC Prescribing Infor mation
The common treatment- emer gent AEs in the FTC Prescribing Information will be summarized 
by PT, in descending order of total frequency . The associated PTs are the following:
Headache 
Diarrhea
Nausea 
Fatigue 
Dizziness
Depression
Insomnia
Abnormal dreams
Rash
Abdominal pain
Asthenia
Cough
Rhinitis.
A by-subject listing will be provided for AEs with PT terms above for all enrolled subjects . 
8.3.7.3. Cardiovascular or Cerebrovascular Events
Preferred terms for cardiovascular or cerebrovascular events are from relevant Standardised 
MedDRA Query (SMQ). The selected PT listing was provided b y Gilead PVE and reviewed b y 
Gilead medical monitors (see details in Appendix 4).
A data listing of cardiovascular or cerebrovascular events will be provided
for the B/F/TAF 
Safety  Anal ysis Set .
8.3.7.4. Hepatic Events
Preferred terms for hepatic events are from 15 relevant SMQs , which are identified as 
non-infectious and non -congenital hepatobiliary  disorders . The selected PT listing was provided 
by Gilead PVE and reviewed by  Gilead medical monitors (see details in Appendix 5).
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 37 02 December 2019A data listing of hepatic events will be provided for the B/F/TAF Safet y Analysis Set .
8.4. Laboratory Evaluations
Laboratory  data collected during the study  will be anal yzed and summarized using both 
quantitative and qualitative methods. Summaries of laboratory  data will be provided for the 
E/C/F/TAF Safet y Anal ysis Set and B/F/TAF Safety  Anal ysis Set .The analy sis will be based on 
values reported in conventional units. When values are below the lower limit of quantitation they 
will be listed as such, and the imputed value will be use d for the purpose of calculating summary  
statistics as specified in Section 3.7. 
A by -subject listing for laboratory  test results will be provided by  subject ID number and visit in 
chronological order for hematology  and serum chemistry  separately . Values falling outside of the 
reference range and/or having a sev erity grade of 1 or higher on the Gilead Gradin g Scale for 
Severity  of Adverse Events and Laboratory  Abnormalities will be flagged in the data listings, as 
appropriate.
8.4.1.
Summaries of Numeric Laboratory Results
Desc riptive statistics will be provided for each laboratory  test specified in the study  protocol as 
follows:
Baseline value 
Value at each postbaseline anal ysis window
Change from baseline at each postbaseline anal ysis window 
In addition, p ercentage change fr om baseline at each postbaseline analy sis window will also be 
provided for biomarker PTH .
A baseline laboratory  value for the E/C/F/TAF phase will be defined as the last nonmissing value 
obtained on or prior to the date of first dose of E/C/F/TAF study  drug. A baseline laboratory  
value for the B/F/TAF OL phase will be defined as the last nonmissing value obtained on or 
prior to the date of first dose of B/F/TAF stud y drug. Change from baseline to a postbaseline 
visit will be defined as the postbaseline valu e minus the baseline value. The mean, median, Q1, 
Q3, minimum, and maximum values will be display ed to the reported number of digits; SD 
values will be display ed to the reported number of digits plus 1.
In the case of multiple values in an anal ysis window, data will be selected for anal ysis as 
described in Section 3.8.3 .
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 38 02 December 2019Calcium Corrected for Albumin
Calcium corrected for albumin will be calcula ted and summarized . The following formula will 
be used when both serum calcium and albumin results for a given blood draw are available and 
serum albumin value is < 4.0 g/dL. 
Calcium corrected for albumin (mg/dL)  serum calcium (mg/dL) + 0.8 (4.0 albumin (g/dL)). 
Toxicity  grading for calcium will be applied based on the corrected values.
Estimated GFR
The following formula will be used to calculate eGFR CG: 
eGFR CG(mL/min)  [(140  age(y rs)) weight (kg) (0.85 if female)] / (SCr (mg/dL) 72),
where weig ht is total body  mass in kilograms, and SCr is serum creatinine. 
8.4.2. Graded Laboratory Values
The Gilead Grading Scale for Severity  of Adverse Events and Laboratory  Abnormalities will be 
used for assigning toxicity grade (0 to 4) to laboratory  results for ana lysis. Grade 0 includes all 
values that do not meet the criteria for an abnormality  of at least Grade 1. For laboratory  tests 
with criteria for both increased and decreased levels, analyses for each direction (ie, increased, 
decreased) will be presented se paratel y.
If there is an y laboratory  toxicity  grading scale overlapping wi th normal reference ranges 
(eg,Grade 1 scale overlaps with normal reference range), laboratory  values within normal range 
will be Grade 0 except for lipid tests.
For trigl ycerides ,LDL, and cholesterol, the protocol -specified toxicity  grade scale is for fasting 
test values, so nonfasting lipid results (or lipid results without known fasting status) will not be 
graded or summarized by toxicity  grades.
For international normalized rat io (INR) of prothrombin time, protocol -specified toxicity  grade 
scale depends on the upper limit of normal range (ULN). While the ULN of INR depends on 
whether a subject is taking anticoagulant medication or not (ie, Not taking oral anticoagulant: 
0.8 - 1.2; Taking oral anticoagulant: 2.0 3.0), the information is not collected in Covance lab. 
As a result, INR will be graded b y assuming thesubject is not taking oral anticoagulant, which is 
a more conservative approach and may  lead to over -
report ingabnorm alities for INR. Since INR 
and prothrombin time are reflex tests; only  an absolute value andnot the toxicity  grade is needed 
for patient management purpose
s; most important ly, the toxi city grades for INR may  be 
over-reported . INR and prothrombin time willnot be included in the laboratory  abnormalities 
summary  table s but will be included in a listing. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 39 02 December 20198.4.2.1. Treatment -Emergent Laboratory  Abnormalities
E/C/F/TAF t reatment- emergent laboratory  abnormalities are defined as values that increase at 
least 1 toxicity  grade from baseline at any  postbaseline time point up to 30 days after the 
permanent discontinuation of E/C/F/TAF study  drug for subjects who do not participate in the 
B/F/TAF OL extension phase or up to the date of the first B/F/TAF study  drug do se for subjects 
who participate in the B/F/TAF OL extension phase . 
B/F/TAF t reatment- emergent laboratory  abnormalities are defined as values that increase at least 
1toxicity  grade from baseline at an y postbaseline time point up to 30 day s after the perma nent 
discontinuation of B/F/TAF stud y drug. 
If the relevant baseline laboratory  value is missing, any  abnormalit y of at least Grade 1 observed 
within the time frame specified above will be considered treatment- emergent.
Fasting glucose and nonfasting gluc ose(including glucose result without a known fasting status)
are graded based on different grading scales as speci fied in the protocol. Treatmen t-emergent 
laboratory  abnormalities will be summarized for fasting glucose. Maximum postbaseline grade, 
instead of treatment -emergent grade, for nonfasting glucose will be summarized, as nonfasting 
glucose was not assessed at baseline visit for most of the subjects; therefore, whether an 
abnormality  is treatment -emergent or not cannot be determined for these subjects. 
8.4.2.2. Summaries of Laboratory  Abnormalities
The following summaries (number and percentage of subjects) for treatment -emergent laboratory  
abnormalities will be provided by lab test ;subjects will be categorized according to most severe 
postbaseline abnormalit y grade for a given lab test
:
Treatment -emergent laboratory  abnormalities
Treatment -emergent Grade 3 or 4 laboratory abnormalities
For all summaries of E/C/F/TAF laboratory  abnormalities, the denominator is the number of 
subjects with any  nonmissing postbaseline values up to 30 day s after the last E/C/F/TAF dose
date for subjects who do not participate in the B/F/TAF OL extension phase or up to the date of 
the first B/F/TAF s tudy drug dose for subjects who participate in the B/F/TAF 
OL extension
phase . 
For all summaries of B/F/TAF laboratory  abnormalities, the denominator is the number of 
subjects with any  nonmissing postbaseline values up to 30 day s after the last B/F/TAF do sedate. 
By-subject listing sof treatment -emergent graded abnormalities and Grade 3 or 4 laboratory  
abnormalities will be provided by subject ID number and visit in chronological order .
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 40 02 December 20198.4.3. Metabolic Laboratory Evaluations
For metabolic assessments, including fasting glucose and the lipid panel (ie, total cholesterol, 
triglycerides, LDL, HDL, total cholesterol to HDL ratio) ,only those measurements under fasting 
status will be summarized. 
Fasting lipid data will also be anal yzed by using the following National Cholesterol Education 
Program (NCEP) ATP III categories {National C holesterol Education Program (NCEP) 2001 }:
For total cholesterol (mg/dL ): < 200, 200
-239, ≥ 240
For LDL (mg/dL): <100, 100-129, 130-159, 160- 189, and ≥ 190 
For HDL (mg/dL): < 40, ≥40 to < 60, and ≥ 60 
For trigl ycerides (mg/dL): < 150, 150 -199, 200-49 9, and ≥ 500
The number and proportion of subjects for the above categories of each lipid parameter will be 
summarized by  its baseline category  at Weeks 24 , 48, 72, and 96 for the E/C/F/TAF Safety  
Analy sis Set and at Weeks 24 and 48 for the B/F/TAF Safety  Anal ysis Set .
In addition, the number and proportion of subjects in the E/C/F/TAF Safet y Analysis Set who 
took lipid modify ing medication at study  entry andinitiated medication during the E/C/F/TAF 
phase and the number and proportion of subjects in the B/F/TAF Safet y Analysis Set who took 
lipid modify ing medication at the start of the B/F/TAF OL extension phase and initiated 
medication during the B/F/TAF OL extension phase will be provided. 
A lipid modify ing medication is defined as a medication with drug class (Anatomical 
Therapeutic Chemical drug class Level 2)  “LIPID MODIFYING AGENTS” and CMDECOD 
containing the wording of “STATIN”.
A sensitivity  anal ysis of fasting lipid tests (including total cholesterol , LDL, HDL, trigl ycerides, 
and total cholesterol to HDL ratio) will be performed using the E/C/F/TAF Safety  Anal ysis Set 
by excluding subjects who took lipid modify ing medication at study  entry  or initiated lipid 
modify ing medication during the study  prior to Week 96: baseline, postbaseline, and changes 
from baseline at Week 96 will be summarized. Only  subjects with both baseline and Week 96 
postbaseline values will be included in the analy sis. 
A sensitivity  anal ysis of fasting lipid tests (including total cholesterol, LDL, HDL, trigl ycerides, 
and total cholesterol to HDL ratio) will be performed using the B/F/TAF Safety  Anal ysis Set by 
excluding subjects who took lipid modify ing medication at the start of the B/F/TAF OL 
extension phase or initiated lipid m odify ing medication during the B/F/TAF OL extension phase : 
baseline, postbaseline, and changes from baseline at Weeks 24 and 48 willbe summarized. Only  
subjects with both baseline and Week 48 postbaseline values wil l be included in the anal ysis. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 41 02 December 2019Median ( Q1, Q3) of change from baseline in fasting metabolic assessments over time will be 
plotted. 
8.4.4. Liver -Related Laboratory Evaluations
Liver -related abnormalities after initial study  drug dosing will be examined and summarized 
using the number and percentage of subjects who were reported to have the following laboratory  
test values for postbaseline mea surements (seeAppendix Table 4):
Individual Test:
Aspartate aminotransferase (AST): (a) > 3 ULN , (b) > 5 ULN, (c) > 10 ULN, 
(d)> 20ULN
Alanine aminotransferase (ALT): (a) > 3 ULN, (b) > 5  ULN, (c) > 10 ULN,
(d)> 20ULN
AST or ALT: (a) > 3 ULN, (b) > 5  ULN, (c) > 10 ULN, (d) > 20ULN
Total bilirubin: (a) > 1 ULN, (b) > 2  ULN
Alkaline Phosphatase (ALP): > 1.5  ULN
AST or ALT > 3  ULN and total bilirubin: (a) > 1.5 ULN, (b) > 2  ULN
AST or ALT > 3 
ULN and total bi lirubin > 2 ULN and ALP < 2  ULN
The E/C/F/TAF 
summary  will use data from all postbaseline visits up to 30 day s after the 
lastdose of E/C/F/TAF study  drug for subjects who do not participate in the B/F/TAF OL 
extension phase or up to the date of the first B/F/TAF stud y drug dose for subjects who 
participate in the B/F/TAF OL extension phase . 
The B/F/TAF summary  will use data from all postbaseline visits up to 30 day
s after the last dose 
ofB/F/TAF study  drug .
For individual laboratory tests, subjects will be counted once based on the most severe 
postbaseline value .For both the composite endpoint of AST or ALT and total bilirubin, and the 
composite endpoint of AST or AL T, total bilirubin, and AL P, subjects will be counted once 
when the criteria are met at the same postbaseline visit date. T he denominator is the nu mber of 
subjects in the E/C/F/TAF Safet y Anal ysis SetorB/F/TAF Safety  Anal ysis Set with nonmissing 
postbaseline values of the tests in evaluation at the same postbaseline visit date. 
In addition, baseline, postbaseline, and change from baseline in AST, ALT, AL P, and total 
bilirubin will be summarized by  visit using descriptive statistics.
Subjects with AST or ALT > 3 ULN will also be listed. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 42 02 December 20198.5. Vital Signs and Body Weight
Descriptive statistics will be provided for vital signs and body  weight as follows: 
Baseline value
Value at each postbaseline anal ysis window
Change from baseline to each postbaseline anal ysis window
A baseline value for the E/C/F/TA F phase will be defined as the last nonmissing value obtained 
on or prior to the date of first dose of E/C/F/TAF study  drug. A baseline value for the B/F/TAF 
OL phase will be defined as the last nonmissing value obtained on or prior to the date of first 
dose of B/F/TAF stud y drug. Change from baseline to a postbaseline visit will be defined as the 
postbaseline value minus the baseline value. 
In the case of multiple values in an anal ysis window, data will be selected for anal ysis as 
describe din Section 3.8.3 . 
A by -subject listing of vital signs , body  weight, height, and BMI will be provided by  subject ID 
number and visit in chronological order. 
8.6. Prior and Concomita
nt Medications
8.6.1. Nonstudy-Drug Antiretroviral (ARV) Medications
Any nonstudy -drug ARV medications used prior to, during, or after the study  (ifcollected) will 
be coded using the GSI- modified World Health Organization (WHO) Drug Dictionary for ARV 
medication s. The WHO preferred name and drug code will be attached to the clinical database. 
All nonstudy -drug ARV medications will be listed. No inferential statistics will be provided.
8.6.1.1. Nonstudy -Drug ARV Medication Received at Baseline
Nonstudy -drug ARV medication with an end date 1 or 2 day s before the first dose date of 
E/C/F/TAF study  drug will be considered as nonstudy -drug ARV medication received 
immediately  prior to the first E/C/F/TAF dose date of study  drug (or prior ARV used at baseline
[pre-switch] ). 
Nons tudy-drug ARV medication received immediately  prior to the first dose date of E/C/F/TAF 
study  drug will be summarized by  preferred name for subjects in the E/C/F/TAF Safet y Anal ysis 
Set. Multiple drug use (by preferred name) will be counted only  once per s ubject. Preferred 
names will be presented by  descending order of the total frequency . No inferential statistics will 
be provided. 
8.6.1.2. Nonstudy -Drug ARV Medication Received Prior to the First Dose Date of Study  
Drug
Nonstudy -drug ARV medication received prior to the first dose date of E/C/F/TAF study  drug 
will also be summarized as a separate table. Results will be summarized in the same way  as 
described for prior ARV used at baseline in Section 8.6.1.1. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 43 02 December 20198.6.2. Concomitant Non -ARV Medications
Concomitant non-ARV medications (ie, medications other than study  drug that are taken while 
receiving stud y drug) will be coded using the WHO Drug Dictionary . The WHO preferred name 
and drug code will be attached to the clinical database. Use of concomitant non-ARV 
medications from Study Day  1 up to the date of last dose of E/C/F/TAF study  drug will be 
summarized (number and percentage of subjects) bypreferre
dname for the E/C/F/TAF Safet y 
Analy sisSet.Use of concomitant non- ARV medications from B/F/TAF S tudy Day  1 up to the 
date of last dose of B/F/TAF study  drug will be summarized (number and percentage of subjects) 
bypreferred name for the B/F/TAF Safety  Anal ysisSet.Multiple drug use (by  preferred name) 
will be counted once only per subject. The summary will be presented by  decreasing total 
frequency .
If the start or stop date of a non-ARV medication is incomplete, the month and y ear (or y ear 
alone if 
month is not recorded) of start or stop date determine whether the non -ARV is
concomitant or not. The medication is concomitant if the month and y ear of start or stop (or year 
of the start or stop) of the medication do esnot meet either of the following cr iteria:
The month and y ear of start of the medication is after the date of the last dose of study  drug
The month and y ear of stop of the medication is before the date of the first dose of study  drug 
If the start and stop date of a non-ARV medication iscomplete , the s tart date is not after the 
lastdose date, and the stop date is not before the first dose date, or the non -ARV medication is
marked as ongoing and start date is on or before the last dose date, the non -ARV medication is
concomitant.
Subject s with any  non- ARV concomitant medications will be listed. No inferential statistics will 
be provided.
8.7.
Electrocardiogram Results
A shift table of the investigators’ assessment of ECG results at each scheduled postbaseline visit 
(Weeks 48 and 96 for the E/C/F/TAF Safe ty Analy sisSet and Week 48 for the B/F/TAF Safety  
Analy sis Set ) compared with baseline values will be presented 
using the following categories: 
normal ;abnormal ,not clinically  significant ;abnormal ,clinically  significant ; andmissing. The 
number and percentage of subjects in each cross -classification group of the shift table will be 
presented. Subjects with a missing value at baseline or postbaseline will not be included in the 
denominator for percentage calculation. No inferential statistics will be provided. 
A by-subject listing 
for ECG assessment results will be provided by subject ID number and visit 
in chronological order .
8.8. Health care Utilization Assessment
The number of hospitalizations, unplanned visits for a healthcare issue, and unplanned specialt y 
care provider visits for a healthcare issue since the last study  visit were summarized for the 
Week 96 anal ysis and will not be 
repeated for the final anal ysis.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 44 02 December 2019A listing of health care utilization assessment data will be provided by  subject.
8.9. Other Safety Analysis
A data listing will be provided for subjects experiencing pregnancy  during the study . Phy sical 
examinatio n data were not collected in the eCRF; therefore ,there is no analy sis for these data.
8.10. Changes From Protocol -Specified Safety Analyses
No change from protocol -specified safet y anal yses is planned.
Genvoya/B iktarvy 
GS-US-292-1825 
Statistical Analysis Plan 
9. PHARMACOKINETIC ANALYSES Version I 
Durin g the B/F/f AF OL extension phase, at Weeks 4 OL, 24 OL, and 48 OL, on the day of 
hemo dialysis, a sparse timed blood sample was to be collected from all subjects within 10 
minut es prior to hemodial ysis initi ation . Predose (within 30 minut es prior to study drug 
administration) blood draws for plasma samples were also collected at these visits. 
Plasma concentrat ions of bictegrav ir from the pre-hemo dialysis and pre-dose (post-
hemo dialysis) PK draws at Weeks 4 OL, 24 OL, and 48 OL will be listed for all subjects for the 
BIF ff AF Plasma PK Analysis Set. 
Concentrat ion samples will be smmnariz ed using descriptive statistics (sample size, mean, SD, 
coeffic ient of variation [%CV ], minimum , medi an, maximum , Q 1, Q3, geometric mean, and its 
95% CI) for the B/F/T AF Plasma PK Analysis Set. For concentrat ion values below the limit of 
quantitation (BLQ ), the nmnb er of subjects with values BLQ will be presente d. 
Plasma PK samplin g details and study drug administration records for plasma PK samples for the 
B/F/f AF OL extens ion phase will be listed. 
CONFI DENT IAL Page 45 02 December 2019 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 46 02 December 201910. PATIENT  REPOR TED OUTCOME S
Patient reported outcomes (PRO) include the following assessments:
Medication Adherence Questionnaire (assessed at all protocol planned visits through 
Week 96 for E/C/F/TAF phase )
HIV Treatment Satisfaction Questionnaire Status (HIV-TSQ s) (assessed at baseline, 
Weeks 4, 24, 48, 72, 96, and End of E/C/F/TAF Visit for E/C/F/TAF phase and at Weeks 4
OL, 24OL, and 48 OLfor B/F/TAF 
OL extension phase)
HIV Treatment Satisfaction Questionnaire Change (HIV -TSQ c) (assessed at Weeks 24, 48, 
72, 96, and End of E/C/F/TAF Visit for E/C/F/TAF phase)
Medical Outcome Study  Short Form (SF -36)(assessed at Baseline, Weeks 24, 48, 72, 96, and 
End of E/C/F/TAF Visit for E/C/F/TAF phase and at Weeks 4 OL, 24OL, and 48 OLfor 
B/F/TAF OL extension phase)
The Medic ation Adherence Questionnaire will be listed only .
The HIV -TSQs, HIV -TSQc, and SF -
36 results will be summarized using the E/C/F/TAF Safet y 
Analy sis Set. D ata collected up to 30 day s after the last dose date of E/C/F/TAF 
study  drug for 
subjects who do not participate in the B/F/TAF OL extension or up to the date of the first 
B/F/TAF stud y drug dose for subjects who participate in the B/F/TAF OL extension will be 
included in summaries. 
The HIV -TSQs and SF -36 results will also be summarized using the B/F/TAF Safety Analysis 
Set.Data collected up to 30 day s after the last dose date of B/F/TAF study  drug will be included 
in summaries.
Unless otherwise stated, multiple responses and out of range responses will be set to missing and
missing responses will not be imputed. The PRO data will be listed .
10.1. Medication Adherence Questionnaire
Adherence wasassessed by  the medication adherence questionnaire that includes a VAS and 2 
additional questions.
For the VAS, the subject is asked to describe their adherence to their ARV regimen by  using a 
linear scale (0% 100%) to indicate what percent of medication was taken in the last 30 days 
(0%  taken none of prescribed anti -HIV medication, and 100%  taken alldosesof prescribed 
anti-HIV medication). The 2 additional questions ask how man y days the subject has missed 
medication in the last 30 day s and how many  days the subject ha s missed medication in the 
last4days. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 47 02 December 2019A listing will be provided for subject response tothe VAS questionnaire. 
10.2. HIV Treatment Satisfaction Questionnaire
Both HIV-TSQ sand HIV-TSQc form shave10 questions about the current treatment regimen.
For the Status form, the response stothose questions range from (6) very satisfied, to (0) very 
dissatisfied; for the Change form, the response stothose questions range from (3) much more 
satisfied now, to (- 3) much less satisfied now, with the exception of the following questions:
a)How well controlled do you feel your H IV has been recentl y? For Status form: (6) very well 
controlled, to (0) very poorly  controlled ; for Change form: (3)much better controlled now, to 
(
-3) much worse controlled now;
b)How convenient have you been finding your treatment to be recently ? For Status form: 
(6)very convenient, to (0) very inconvenient ; for Change form: (3)much more convenient 
now, to (- 3) much less convenie nt now;
c)How flexible have you been finding your treatment to be recentl y? For Status form: 
(6)very flexible, to (0) very inflexible ; for Change form: (3)much more flexible now, to 
(
-3)much less flexible now;
d)On Status form only : Would y ou recommend y ourpresent treatment to someone else with 
HIV? (6)Yes, I would definitely  recommend the treatment, to (0) No, I would definitely  not 
recommend the treatment.
e)On Change form onl y: How likely  would y ou be to recommend your present treatmen t to 
someone else wi th HIV? (3) much more likel y to recommend the treatment now, to 
(
-3)much less likel y to recommend the treatment now.
A treatment satisfaction scale total will be calculated as the sum of the responses to the 
10 que stion items on the S tatus form, ranging f rom 0 to 60, and on the Change form, rangin g
from 30 to 30. If the number of missing responses is ≥ 2 then the treatment satisfaction scale 
total will be set to missing ;otherwise, the missing item score will be imputed by  the average of 
the non- missing i tem responses from the same subject at the same visit and the treatment 
satisfaction scale total will be calculated.
A descriptive summary  of the number and percent of subjects with responses to each question 
and the treatment satisfaction scale total will be provided for HIV -TSQ sform and the HIV-TSQ c
form by visit .
Two listings will be provided for subject responses to HIV-TSQ sand HIV-TSQc forms at all 
visits for each subject, respectively . 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 48 02 December 201910.3. SF-36(Version 2) Health Survey
The SF -36 Version 2 is a self-reported, generic, comprehensive, and widely  used questionnaire 
that is designed to measure health -related quality  of life in the general population, as well as in 
subject groups with diverse chronic diseases including HIV/AIDS. Responses from the 36 items 
are used to construct 8 health domains including phy sical functioning, social functioning, general 
health, vitality , bodily  pain, mental health, role capacity -physical, and role capacity -emotional. 
Furthermore, 2 summary  scores , the Phy sical Componen t Summary  (PCS) and Mental 
Component Summary  (MCS) scores , aggregate information from the 8 SF-36 dom ains in a way  
that captures 80% to 85% of the variance in the 8 domains. 
10.3.1. Scoring the SF -
36
The 8 domains and 2 component summary  scores of the SF -36 will be calculated according to 
“How to Score Version 2 of the SF -36 Health Survey  (Chapters 6 and 7)” {Maruish 2011}
published by  Quality Metric Inc. Scores for each of the 8 domain s
,including PCS and MCS ,
range from 0 to 100 with a higher score indicating a better functioning. 
10.3.2. SF-36 Statistical Analysis Method
Scores and change from baseline for each domain, PCS, and MCS will be summarized by  visit 
using descriptive statistics (sample size, mean, SD , median, Q1, Q3, minimum ,and maximum) . 
A by-subject listing for the scores for each domain, PCS, and MCS will be provided. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 49 02 December 201911. REFERENCES
Maruish ME. User's manual for the SF -36v2 Health Survey . 3rd ed. Lincoln, RI : Qualit y Metric 
Incorporated.; 2011. 
National Cholesterol Education Program (NCEP). Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary . 
National Institute of Health  May , 2001.
U. S. Department of Health and Human Services, Food and Drug Administration (FDA), Center 
for Drug Evaluation and Research (CDER). Human I mmu nodeficiency  Virus -1 
Infection: Developing Antiretroviral Drugs for Treatment. Guidance for Industry . 
Silver Spring, MD.  November, 2015.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 50 02 December 201912. SOFTW ARE
SAS(SAS I nstitute Inc., Version 9.4, Cary , NC) is to be used for all programming of tables, 
listings, and figures.
nQuery  Advisor(Statistical Solutions L td., Version 6.0, Cork, Ireland) 
wasused for the sample 
size and power calculation.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 51 02 December 201913. SAP REVISION
Revision Date
(dd m onth, yyyy) Section Summary of Revision Reason for Revision
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 52 02 December 201914. APPENDICES
Appendix 1. Study Procedures Table (E/C/F/TAF Phase)
Appendix 2. Study Procedures Table (Open Label Rollover Extension)
Appendix 3. Flow chart of US FDA -defined Snapshot Algorithm for Switch Trial
Appendix 4. Cardiovascular or Cerebrovascular Events
Appendix 5. Hepatic Events
Appendix 6. TFL Mocks
Appendix 7. Programming Specifications
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 53 02 December 2019Appendix 1. Study Procedures Table (E/C/F/TAF Phase)
Study Procedure ScreenaDay 
1bWeek 2 to Week 96cPost 
Week 96End of 
E/C/F/TAF 
Visit30-Day 
Follow -
updESDDe2 4 8 12 24 36 48 60 72 84 96Every 
12Weeks
Written Informed Consent X
Medical History X
Complete Physical 
Examinationf X X X X X X
Symptom directed Physical 
Examinationg X X X X X X X X X X X
Vital Signs and Weight X X X X X X X X X X X X X X X XhX
Height X
12Lead ECG X X X X X
Chemistry ProfileiX X X X X X X X X X X X X X X X X
Metabolic AssessmentsjX XjXjXjXjXwX
Serum Pregnancy TestkX X X X X X X X X X X X X X X X X
CD4+ T Cell Count X X X X X X X X X X X X X X X X X
Plasma HIV 1 RNAlX X X X X X X X X X X X X X X X X
HIV 1 Genotype/PhenotypemX X X X X X X X X X X X X X
Estimated eGFR X X X X X X X X X X X X X X X X
Hematology profilenX X X X X X X X X X X X X X X X X
Plasma Storage Samples X X X X X X X X X X X X X X X
Concomitant Medications X X X X X X X X X X X X X X X X X
HBV and HCV SerologypX
CCI
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 54 02 December 2019Study Procedure ScreenaDay 
1bWeek 2 to Week 96cPost 
Week 96End of 
E/C/F/TAF 
Visit30-Day 
Follow -
updESDDe2 4 8 12 24 36 48 60 72 84 96Every 
12Weeks
Adverse Events X X X X X X X X X X X X X X X X X
SF36qX X X X X X X
HIV TSQqX X X X X X X X X
VAS X X X X X X X X X X X X X
Health Utilization AssessmentrX X X X X X X X X X X X X
Drug Dispensation and 
AccountabilityX XsX X X X X X X X X X X XxXs
Predose Whole Blood Sample 
Collectiont X X
Whole Blood Storage SamplevX
a Evaluations to be completed within 30 days prior to Day 1.
b Subjects will be dispensed study drug on the Day 1 Visit; initiation of treatment with the study drug must take place within 24 hours after the Day 1 Visit.
c All study visits are to be scheduled relative to the Day 1 Visit date. Visit windows are ± 2 days of the protocol specified date through Week 12, ± 6 days of the protocol 
specified date through Week 48, except Week 48. Weeks 48 Visit window is ± 6 weeks of the protocol specified date. Week 48 V isit should be completed within ± 6day 
window, unless otherwise specified by the Sponsor. Following the Week 48 Visit, study visits are to be completed within ± 6 days of the protocol specified date through 
Week 84. The visit window at Week 96 will be ± 6 weeks of the protocol specific visit date. Unless notified by the Sponsor, Week 96 V isitshould be completed within 
± 6 days of the protocol specific visit date.
d Required for those subjects who complete Week 96 Visit or those subjects who prematurely discontinue study drug and do not continue in the study through at least 
onesubsequent visit after the Early Study Drug Discontinuation Visit. For the purpose of scheduling a 30 Day Follow Up Visit, a ± 6days window may be used.
e Early Study Drug Discontinuation Visit to occur within 72 hours of last dose of study drug. Subjects will be asked to continue attending the scheduled study visits through 
Week 96, if the subject discontinues study drug prior to completion of Week 96 Visit.
f Complete physical examination (urogenital/anorectal exams will be performed at the discretion of the Investigator).
g Symptom directed physic al examination as needed
h Weight only
i
Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumi n, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, PT/INR, amylase (reflex lipase testing is performed in subjects with total amylase 
>1.5×ULN) and PTH. At Day 1, Weeks 24, 48, 72, and 96 analyses of glucose will be done as part of the fasting metabolic assessments and not as part of the chemistry 
profile. PT/INR will be included in the chemistry profile at Screening, Weeks 24 and 48 only. This sample should be drawn pri or to hemodialysis. The timing of draw and 
timing of hemodialysis should be recorded.
CCI
Genvoya/ B iktarvy 
GS-US-292-1825 
Statistical Analysis Plan Vers ion I 
Fasting glucose and lipid pane l (tota l chol estero l, HDL, direct LDL, triglycerides). If the subject has not fasted prior to the visit, the visit m ay proceed , but the sub ject must 
return within 72 hours in a fasted state to draw blood for the metabo lic assess ments. At Wee ks 24, 48, 72, and 96 analyses of glucose will be done as part of fasting metabo lic 
assess ments and not as part of the chem istry profile. 
k Fema les of childbea ring potent ial only. FSH test is re.qu ired for fema le subjects who have stopped menst mating for 2:: 1 2 months but do not have documentat ion of ovarian 
hom10na l failure. 
If the HIV I R NA value is 2:: 50 copies/m L a retest should be collected at a schedu led or unschedu led visit, 2 4 weeks after the date of the original test (except for screening 
and base line results). See Protoco l Section 6. 7. 1. 
m HIV I genotype/p henotype resistance testing only conducted for subjects with confi m1ed virologic rebound with HIV I R NA value 2:: 400 copies/m L. Subjects should be 
managed acco rding to the Vi rologic Rebound Schema (see Protoco l Section 6. 7.1 ). HIV I genotype /phenotype samp le collection to occu r if subject's HIV I R NA lab values 
meet the criteria descr ibed in this section. 
n CBC wi th different ial and latelet count I ' 
p See Protoco l Sectton 4.2 to con m11 subject eligib ility prior to enro llment. 
q SF 36 is to be comp leted by subjects at Day I, Wee k 24, Wee k 48, Week 72, and Week 96 Visits. HIV T SQs should be comp leted by the subjects at Screen ing, Day I, 
Wee k 4, Wee k 24, Wee k 48, Wee k 72, Wee k 96 and ESDD Visits. HIV T SQc should be comp leted by the subjects at Week 24, Wee k 48, Wee k 72, Wee k 96 and ESDD 
Visits. 
r Subjects will be asked about their health utilization at Day I Visit and every visit thereafter , includ ing the ESDD and Unsc heduled Visits. 
s D mg accountab ility only; study dmg w ill not be dispensed at these visits. 
t At Week 4 or Week 1 2, pre dose whole blood samp le will be collected for subjects enro lled in the study. Samp le collection should occur within 30 minutes prior to the study 
dmg administration which sh ould be observed on site. PBMC rocess ing will be com leted b the centra l laborato . I ' 
V 
w 
X 
CON FIDENTIAL Page 55 02 December 2019 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 56 02 December 2019Appendix 2. Study Procedures Table (Open Label Rollover Extension)
Study ProcedureEnd of E/C/F/TAF 
VisitEnd of Weeka, c
30-Day Follow - updESDDeWeek 4 OL Week 12 OL Week 24 OL Week 36 OL Week 48 OL
Complete Physical ExaminationfX X
Symptom directed Physical 
Examinationg X X X X X X
Vital Signs and Weight X X X X X X XhX
12Lead ECG X X X
Chemistry ProfileiX X X X X X X X
Metabolic AssessmentsjX X X
Serum Pregnancy TestkX X X X X X X X
CD4+ T Cell Count X X X X X X X X
Plasma HIV 1 RNAlX X X X X X X X
HIV 1 Genotype/PhenotypemX X X X X X X
PK SamplingpX X X
Estimated eGFR X X X X X X X
Hematology profilenX X X X X X X X
Plasma Storage Samples X X X X X X X
Concomitant Medications X X X X X X X X
Adverse Events X X X X X X X X
SF36 X X X X X
HIV TSQ X X X X X
Drug Dispensation and 
AccountabilityX X X X X X Xb
a Open label study drug, B/F/TAF FDC will be dispensed to subjects participating in the Open Label Rollover extension for at least 48 weeks.
b Drug accountability only; study drug will not be dispensed at these visits
c All study visits are to be scheduled based upon theWeek 96 Visit or End of E/C/F/TAF Visit date (whichever occurs later) . The Week 4 OL Visit should be completed within 
±2 days of the protocol specifi ed visit date. All other Study visits are to be completed within ± 6 days of the protocol specified visit date, unless otherwise specified by the 
Sponsor .
CCI----------------------------------------------------------------
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 57 02 December 2019d Required for those subjects who complete End of E/C/F/TAF Visit or those subjects who prematurely di scontinue study drug during the Open Label extension phase . For the 
purpose of scheduling a 30 Day Follow Up Visit, a ± 6days window may be used.
e Early Study Drug Discontinuation Visit to occur within 72 hours of last dose of study drug. 
f Complete physica l examination (urogenital/anorectal exams will be performed at the discretion of the Investigator).
g Symptom directed physical examination as needed
h Weight only
i Chemistry profile: alkaline phosphatase, AST, ALT, GGT, total bilirubin, direct and indirect bilirubin, total protein, albumin, LDH, CPK, bicarbonate, BUN, calcium, 
chloride, creatinine, glucose, phosphorus, magnesium, potassium, sodium, uric acid, PT/INR, amylase (reflex lipase testing is performed in subjects with total amylase 
>1.5×ULN) and PTH . At End of E/C/F/TAF Visit, Week 24 OL, and Week 48 OL analyses of glucose will be done as part of the fasting metabolic assessments and not as 
part of the chemistry profile. This sample should be drawn prior to hemodialysis. The timing of draw and timing of hemodialysis should be recorded.
j Fasting glucose and lipid panel (total cholesterol, HDL, direct LDL, triglycerides). If the subject has not fasted prior to t he visit, the visit may proceed, but the subject must 
return within 72 hours in a fasted state to draw blood for the metabolic assessments. At End of E/C/F/TAF Visit, Week 24 OL, and Week 48 OL analyses of glucose will be 
done as part of fasting metabolic assessments and not as part of the chemistry profile. 
k Females of childbearing potential only. FSH test is required for female subjects who have stopped menstruating for ≥ 12 months but do not have documentation of ovari an 
hormonal failure.
l If the HIV 1 RNA value is ≥ 50 copies/mL a retest should be collected at a scheduled or unscheduled visit, 2 3 weeks after the date of the original test (except for screening 
and baseline results). See Protocol Section 6.7.3 .
m HIV 1 genotype/phenotype resistance testing only conducted for subjects with confirmed virologic rebound with HIV 1 RNA value ≥ 200 copies/ mL. Subjects should be managed 
according to the Virologic Rebound Schema ( see Protocol Section 6.7.3 ). HIV 1 genotype/phenotype sample collection to occur if subject ’s HIV 1 RNA lab values meet the 
criteria described in this section.
n CBC with differential and platelet count
p At Week 4 OL, Week 24 OL and Week 48 OL study visits, on the day of hemodialysis, a sparse timed blood sample will be coll ected within 10 minutes before hemodialysis 
initiates from all subjects. Pre dose (within 30 minutes prior to study drug administration) blood draws for plasma samples will also be collected at these vi sits. Study drug 
administration will be observed. Plas ma concentrations of BIC may be determined. Plasma concentrations of other analytes may also be explored.
CCII 
Genvoya/B iktarvy 
GS-US-292-1825 
Statistical Analysis Plan Version I 
Appendix 3. Flowchart of US FDA-defined Snapshot Algorithm for Switch Trial 
The following flowchart for US FDA-defined snapshot algorithm in based on the US FDA 
Guidance on Hmnan Immunod eficiency Virus-1 Infection: Developin g Antiretrovira l Drugs for 
Treatment {U.S. Department of Health and Human Services 2015 } 
Yes Is there at least I on-
treatment* HIV- l RNA 
collected in the Snapshot 
window? 
Is the last available on-treatment* 
HIV- I RNA in the Snaps hot 
window< 50 copies/mL? 0 
Is study drug premat urely 
discontinued on or prior to the 
uppe r limit of the Snaps hot 
window? 
Yes 
Yes Is discontinua tion of the study 
drug due to Lack of Efficacy ? 
HIV-1 RNA < 
50 copies /mL 
HIV-I RNA~ 
50 copies /mL No 
Is discontinuation of the study 
drug due to AE/Death ? 
Yes 
Is the last available on- ls the last available on-
treatment* HIV-I RNA< treatme nt* HIV-I RNA < 
50 copies/mL 50 copies/mL 
Yes 
No Viro logic Data : 
iscontinued Study Drug 
Due to Other Reasons 
and Last HJV-1 RNA < 
50 copies /mL No Viro logic Data: 
Discontinued Study 
Drug Due to AE/Death 
and Last HIV-1 RNA < 
50 copies /m L No 
No Virologic Data: 
Missing Data During 
Window but on Study 
Drug 
* On-treatment values include 1) data collected up to 1 day after the last dose date for subjects who 
prema turely disco ntinued or comp leted study drug or 2) all the data for subjects who were ongoing 
CON FIDENTI AL Page 58 02 December 2019 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 59 02 December 2019Appendix 4. Cardiovascular or Cerebrovascular Event s
An adverse event record will be flagged a s a cardiovascular or cerebrovascular event if its 
MedDRA PT 
is included in the pre -specified PT list, which includes all PTs from the narrow 
search of the following 3 SMQs under MedDRA v22.0 provided by Gilead PVE (search name: 
Ischemic cardiac and cerebral events narrow ) and reviewed b y Gilead medical monitors.
SMQ Source
Cardiovascular or Cerebrovascular 
EventsIschaemic central nervous system vascular conditions (SMQ) –Narrow  
Scope Term
Myocardial infarction (SMQ) -Narrow  Scope Term
Other ischaemic heart disease (SMQ) -Narrow  Scope Term
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 60 02 December 2019Appendix 5. Hepatic Events
An adverse event record will be flagged as a hepatic event if its MedDRA PT is included in this
pre-
specified PT list , which includes all PTs from the broad search of the following 15 SMQs 
under MedDRA v22.0 provided by Gilead PVE (search name: Non-infectious, non -congenital 
hepatobiliary  disorders ) and reviewed b y Gilead medical monitors
.
SMQ Source
Hepatic Events (HEP)Biliary neoplasms benign (incl cysts and polyps) (SMQ)
Biliary malignant tumours (SMQ)
Biliary tumours of unspecified malignancy (SMQ)
Biliary system related investigations, signs and symptoms (SMQ)
Biliary tract disorders (SMQ)
Gallbladder related disorders (SMQ)
Gallstone related disorders (SMQ)
Cholestasis and jaundice of hepatic origin (SMQ)
Hepatic failure, fibrosis and cirrhosis and other liver damage -related conditions (SMQ)
Hepatitis, non -infectious (SMQ)
Liver neoplasms, benign (incl cysts and polyps) (SMQ)
Liver malignant tumours (SMQ)
Liver tumours of unspecified malignancy (SMQ)
Liver related investigations, signs and symptoms (SMQ)
Liver -related coagulation and bleeding disturbances (SMQ)
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 61 02 December 2019Appendix 6. TFL Mocks
Appendix Table 1. Subject Disposition, All Screened Subjects
Visit GEN
Subjects Screened 75
Screen Failure Subjects Who Were Not Enrolled 15
Subjects Met All Eligibility Criteria and Not Enrolled* 5
Subjects Enrolled 55
Subjects Enrolled and Never Treated 0
Subjects in E/C/F/TAF Safety Analysis Set 55
Subjects in E/C/F/TAF Full Analysis Set 55
Subjects Completing E/C/F/TAF Study Treatment xx (xx.x%)
Subjects Prematurely Discontinuing E/C/F/TAF Study Treatment xx (xx.x%)
Reasons for Prematurely Discontinuing E/C/F/TAF Study 
Treatment
Reason 1 xx (xx.x%)
Reason 2 xx (xx.x%)
Reason x xx (xx.x%)
Subjects Enrolling in B/F/TAF Open Label Extension Phase xx 
Subjects in B/F/TAF Safety Analysis Set xx
Subjects in B/F/TAF Full Analysis Set xx
Subjects Completing B/F/TAF Study Treatment xx (xx.x%)
Subjects Prematurely Discontinuing B/F/TAF Study Treatment xx (xx.x%)
Reasons for Prematurely Discontinuing B/F/TAF Study Treatment
Reason 1 xx (xx.x%)
Reason 2 xx (xx.x%)
Reason x xx (xx.x%)
Subjects Completing Study xx (xx.x%)
Subjects Prematurely Discontinuing from Study xx (xx.x%)
Reasons for Prematurely Discontinuing from Study
Reason 1 xx (xx.x%)
Reason 2 xx (xx.x%)
Reason x xx (xx.x%)
The denominator for percentages of subjects is the number of subjects in the E/C/F/TAF Safety Analysis Set except for the 
categories related to the B/F/TAF Open Label Extension Phase for which the denominator is the number of subjects in the 
B/F/TAF Safety Analysis Set.
The number of screen failures is counted by unique subject based on the date of birth, race, ethnicity, sex, country, and ini tials.
* Among 5 subjects who met all eligibility criteria but were not enrolled, the reasons (N)were: withdrew con sent (4) and 
outside of visit window (1).
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 62 02 December 2019Appendix Table 2. Virologic Outcome at Week 96 (HIV- 1 RNA Cutoff at 50 copies/mL, Snapshot Algorithm), 
Full Analysis Set
GEN
(N=xxx)
HIV-1 RNA < 50 copies/mL xx (xx.x%)
95% CI xx.x% to xx.x%
HIV-1 RNA ≥ 50 copies/mL xx (xx.x%)
95% CI xx.x% to xx.x%
HIV-1 RNA ≥ 50 copies/ mLin Week 96 Window xx (xx.x%)
Discontinued Study Drug Due to Lack of Efficacy xx (xx.x%)
Discontinued Study Drug Due to AE/Death and Last Available 
HIV-1 RNA ≥ 50 copies/mLxx (xx.x%)
Discontinued Study Drug Due to Other Reasons* and Last Available 
HIV-1 RNA ≥ 50 copies/mLxx (xx.x%)
No Virologic Data in Week 48Window xx (xx.x%)
Discontinued Study Drug Due to AE/Death and Last Available 
HIV-1 RNA < 50 copies/mLxx (xx.x%)
Discontinued Study Drug Due to Other Reasons* and Last Available 
HIV-1 RNA < 50 copies/mLxx (xx.x%)
Missing Data During Window but on Study Drug xx (xx.x%)
Week 96 window is between Day 631and 714(inclusive).
* Other reasons include subjects who discontinued study drug due to investigator’s discretion, subject decision, lost to follow up, noncompliance with study drug, protocol 
violation, pregnancy, and study terminated by sponsor.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 63 02 December 2019Appendix Table 3. Number and Percentage of Subjects with HIV -1 RNA < 50 copies/mL by Visit , Missing Excluded
GEN
(N = xx)
HIV-1 RNA at Week XX
< 50 copies/mL
95% CI
< 20 copies/mL
< 20 copies/mL Not Detectable
< 20 copies/mL Detectable
20 to < 50 copies/mL 
≥ 50 copies/mL 
The denominator for percentages is the number of subjects in the E/C/F/TAF Full Analysis Set.
The 95% CI for percentage estimate of HIV 1 RNA < 50 copies/mL wa s obtained using Exact method.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 64 02 December 2019Appendix Table 4. Liver -Related Labora tory Test Abnormalities
GEN
(N = xx)
AST
> 3 x ULN xx/xx (xx.x%)
> 5 x ULN xx/xx (xx.x%)
> 10 x ULN xx/xx (xx.x%)
> 20 x ULN xx/xx (xx.x%)
ALT
> 3 x ULN xx/xx (xx.x%)
> 5 x ULN xx/xx (xx.x%)
> 10 x ULN xx/xx (xx.x%)
> 20 x ULN xx/xx (xx.x%)
AST or ALT
> 3 x ULN xx/xx (xx.x%)
> 5 x ULN xx/xx (xx.x%)
> 10 x ULN xx/xx (xx.x%)
> 20 x ULN xx/xx (xx.x%)
Total Bilirubin
> 1 x ULN xx/xx (xx.x%)
> 2 x ULN xx/xx (xx.x%)
Alkaline Phosphatase (ALP)
> 1.5 x ULN xx/xx ( xx.x%)
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 65 02 December 2019GEN
(N = xx)
AST or ALT > 3 x ULN xx/xx (xx.x%)
Total Bilirubin > 1.5 x ULN xx/xx (xx.x%)
Total Bilirubin > 2 x ULN xx/xx (xx.x%)
Total Bilirubin > 2 x ULN and ALP < 2 x ULN xx/xx (xx.x%)
ULN  upper limit of normal.
Denominator for percentage for individual test is the number of subjects in the E/C/F/TAF Safety Analysis Set with at least 1 postbaseline laboratory value.
The most severe postbaseline value per subject was summarized for each laboratory test. For AST, AL T, AST or ALT, and total bilirubin, subjects may be counted in multiple 
categories, eg, subject would be counted in > 3 ULN, > 5 ULN and > 10 ULN if the worst value was > 10 ULN.
For the composite endpoint of AST or ALT, and total bilirubin with or without alkaline phosphatase (ALP), subjects were counted once when the criteria were met at the same 
postbaseline visit date. The denominator is the number of subjects in the S afety Analysis set with nonmissing postbaseline values of the tests in evaluation at t he same postbaseline 
visit date.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 66 02 December 2019Appendix Table 5. Individual Data and Summary Statistics of Plasma Bictegravir Concentration (ng/mL) at 
Protocol -Specified Sampling Times
Subject IDWeek 4
SparseWeek 4
PredoseWeek 24
SparseWeek 24
PredoseWeek 48
SparseWeek 48
Predose
##### -####
##### -####
N
Mean 
SD 
% CV
Median 
Min 
Max 
Q1
Q3
N (LN- scale) 
Geom . Mean 
95% CI(L) 
95% CI(U) 
# BLQ
BLQ  Below Limit of Quantitation.
Geom. Mean  Geometric Mean. LN  Natural log.
PPD
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 68 02 December 2019Appendix 7. Programming Specifications
1)AGE is calculated as follows:
a)AGE (y ears) is calculated from the number of day
s between the date of birth (DOB) and 
Day 1 (first E/C/F/TAF dose date),
b) Use the SAS INTCK function to determine the number of “1st- of-month day s” 
(eg,January  1st, February  1st, March 1st) between DOB and Day 1 (inclusive),
c)Divide the result in (b) by 12,
d)AGE  the integer of the result in (c),
e)If the DOB and Day  1 have the month in common and the birthday  is later in the month 
than the date of Stud y Day 1, then subtract one from the AGE result above.
For subjects enrolled and never dosed with study  drug, age will be calculated from the date 
of enroll ment .
Age for laboratory  test reference range will be based on the age at the sample collection date.
2)All screened subjects refer to all subjects who are scree ned and have a screening number . For 
summarization, same subject is counted only  once. DOB and other demographic information 
such as sex, race, ethnicity , count ry, and initials will be used for identify ing unique screened
subjects. 
3)Screen failure subjects are the subjects who were screened and answered “No” for an y 
inclusion criteria or “Yes” for an y exclusion criteria regardless of which version of protocol 
the subject was consent to.
4)Subjects in the All Enrolled anal ysis set are defined as subjects enrol led into the study . 
IXRSENRL is the source to determine whether the subject is enrolled.
5)In disposition table, the reasons for premature discontinuation are display ed in the order as 
they appear on the eCRF.
6)Body mass index (BMI) is calculated from height in meters (eg, height in cm/100) and 
weight in kilograms as:
BMI will be calculated at baseline. Baseline height and weight will be used for the 
Calculation: Height will be obtained from Vital Signs Performed eCRF at screening visit; 
Weight will be obtaine d from Vital Signs Performed eCRF at the baseline visit; if it i s 
missing, Weight at the screening visit from Vital Signs Performed eCRF will be used. For 
B/F/TAF baseline, the last nonmissing Weight value obtained on or prior to the date of 
first B/F/TAF study  drug will be used.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 69 02 December 2019BMI  (weight [kg]) / (height [meters]2) 
7) Please note, “Not Permitted”, “Unknown”, or missing categories will be excluded for 
percentage calculation. Except for Mode of infection (HIV Risk Factors), where “Unknown” 
will be included for percentage calculation, since a subject may  fit more than 1 HIV risk 
factors, therefore percentage may  add to more than 100%. 
Subjects with Race  “Not Permitted” will also be exclud ed to define Race subgroup 
(ie,black vs. nonblack) for efficacy  subgroup analy sis. 
8) B aseline disease characteristics 
Baseline disease characteristics in Section 5.2will be summarized for both the E/C/F/TAF 
Safety  Anal ysis Set and the B/F/TAF Safet y Analysis Set. Baseline disease characteristics 
collected at enrollment include mode of infection, HIV disea se status, HCV antibody  status, 
medical history  (including Ty pe I or II diabetes, cardiovascular disease, h ypertension, 
hyperlipidemia), smoking status, duration of hemodialy sis, and pre -switch ARVs. These 
characteristics are defined prior to the first dose of E/C/F/TAF. 
The following baseline characteristics will be re- defined for the B/F/TAF summary :
HIV-1 RNA categories (copies/mL ): (a) < 50 and(b) ≥ 50
CD4 cell count (/μL)
CD4 cell count categories (/μL ): (a) < 50, (b) ≥ 50to< 200 , (c) ≥ 200 to < 350, 
(d)≥ 350 to< 500 , and (e) ≥ 500
CD4%
eGFR CG(mL/min)
9)Medical history  of interest at study  entry
Medical history  of diabetes, hy pertension, cardiovascular disease, and hy perlipidemia will be 
summarized at study  entry  (E/C/F/TAF baseline) as baseline disease characteristics. A 
subject who had medical history  of one of these disease s is a subject who experienced at least 
one selected medical history  reported in the Medical History  eCRF , including key words as 
below .
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 70 02 December 2019Hypertension Diabetes Cardiovascular Disease Hyperlipidemia
HYPERTENSION DIABETESCEREBRAL VASCULAR 
ACCIDENTHYPERLIPIDEMIA
HIGH BLOOD 
PRESSUREDIABETICCEREBROVASCULAR 
ACCIDENTDYSLIPIDEMIA
MYOCARDIAL INFARCTION HYPERCHOLESTEREMIA
CONGESTIVE HEART FAILURE HYPERCHOLESTEROLEMIA
CORONARY ARTERY DISEASE HIGH CHOLESTEROL
CORONARY ARTERY 
CALCIFICATIONHIGH TRIGLYCERIDES
PERIPHERAL VASCULAR 
DISEASEELEVATED CHOLESTEROL
CARDIOMYOPATHY HYPERGLYCERIDAEMIA
HEART DISEASE
TRANSIENT ESCHEMIC 
ATTACK
AGINA
ARTERY BLOCKAGE
CARDIOVASCULAR DISEASE
In addition, subject who experienced h ypertension before starting stud y drug according to 
Adverse Event eCRF with reported term includes the key  word “HYPERTENSI ON”. 
10)To calculate years on hemodialy sis at study  entry , please use the Medical History  CRF to 
find the earliest (according to MH start date on Medical History  CRF) hemodialy sis medical 
record containing an y of the following keywords: 
a)“ESRD”
b) “END” + “STAGE” + “RENAL”/“KIDNEY” + “DISEASE”/ “FAILURE”
c)“RENAL”/“KI DNEY”/“HEMO” + “DIALYS IS”
d)“RENAL”/“KIDNEY” + “DISEASE”/“FAILURE” + “SEVERE”/“STAGE_VI”
For each subject, y ear on HD  y ear of first E/C/F/TAF dose date start year of the 
hemodialy sis medical record captured as above + 1. 
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 71 02 December 201911)Smoking status at study  entry
Smoking status at baseline (ie, never smoke d, former smoker, and current smoker) will be 
summarized as part of the baseline disease characteristics. 
Former smoker at baseline refers to the s
ubjects who have stopped the use of an y Cigarettes 
or Cigars before study  day 1 (ie, the first E/C/F/TAF dose date).
Current Smoker at baseline refers to the smokers who have used any Cigarettes or Cigars at 
study  day 1.
Never smoker at baseline refers to subjects who have no record with Ty pe of Substance Use  
“Cigarette s” or “Cigars” on or prior to study  day 1.
How to classify  a subject as never smoker, former smoker, or current smoker at baseline is 
specified as follows:
a)First select onl y records with Type of Substance Use  “Cigarettes” or “Cigars”. Records 
with Type of Substance Use  “Other” (including chew tobacco, e -cigarettes, etc) will not 
be considered as smoking.
b) Second, for each selected substance use record, flag whether it is “Prior”, “Present”, or 
“Post” relative to the first E/C/F/TAF dose date according to the algorithm below. 
c)Finally , (1) the subject will be flagged as “Never” smoker, if the subject has no record 
with Type of Substance Use  “Cigarettes” or “Cigars” or all selected records have a flag 
of “Post”; (2) the subject will be flagged as a “Former” smoker, if an y selected record has 
flag of “Prior” and no record of “Present”; (3) Otherwise, the subject will be flagged as a 
“Current ” smoker, if an y selected records has a flag of “Present”. 
Selected Substance Use Records
Prior No No Yes Yes Yes No No Yes
Present No No No No Yes Yes Yes Yes
Post No Yes No Yes No No Yes Yes
Smoking Status Never Never Form er Form er Current Current Current Current
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 72 02 December 2019Algorithm to flag whether a selected record is “Prior”, “Present”, or “Post” relative to 
the first E/C/F/TAF dose date:
a)The start and stop dates of the selected record are not completely missing (ie , at least year 
is known) or the start date is not missing and record is ongoing. The complete start or 
stop dates will be used to compare with the first dose date whenever possible. Otherwise, 
the month and y ear (or year alone if month is not recorded) of the start or stop dates will 
be used to compare with the first dose date when the start or stop date of the selected 
record is incomplete:
i)The record is flagged as “Prior”, if the stop date is before the first dose date; 
ii)The record is flagged as “Present”, if the start date is on or before the first dose date 
and the stop date is on or after the first dose date, 
or the selected record is marked as 
ongoing and the start date is on or before the first dose date; 
iii)The re cord is flagged as “Post”, if the start date is after the first dose date
b)The start date of the selected record is completel y missing. We assume that the start date 
is before the first dose date, the stop date (or the month and/or y ear of the stop date, if
stop date is incomplete) or “ongoing” will be used to determine whether the selected 
record is “Prior” or “Present” as follows:
i)The record is flagged as “Prior”, if the stop date is before the first dose date or the 
stop date is completed missing and t he record is not marked as ongoing. 
ii)The record is flagged as “Present”, if the stop date is on or after the first dose date or 
the selected record is marked as ongoing.
c)The start date of the selected record is before the first dose date, but the stop date is 
completely  missing and the record is not marked as ongoing. We assume that the end date 
is before the first dose date, the record is flagged as “Prior”.
d) The start date of the selected record is on or after the first dose date, but the stop date is 
completely  missing and the record is not marked as ongoing. This is a data issue, should 
be queried first. However, this record is flagged as “Present” if the start date is on the 
first dose; this record is flagged as “Post” if the start date is after the first dose.
12)Clarification for defining Pre-ARV Categories.
Subjects ar e grouped b y the pre -ARV at baseline (pre-switch). Pre -switch ARVs include 
ARVs that the subject was receiving 1 or 2 day s before the first dose date. For each subject, 
classify  them in each ARV category  perAppendix Table 6.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 73 02 December 2019Appendix Table 6. ARV Category 
Pre-ARV Categories CMTRT3 ABBR INGRED
TDF containing ARVNRTI/INI: Stribild 
(EVG+COBI+FTC+TDF)STB EVG COBI FTC TDF
NRTI/NNRTI: Atripla 
(EFV+FTC+TDF)ATR EFV FTC TDF
NRTI/NNRTI: Complera 
(FTC+RPV+TDF)CPA FTC RPV TDF
NRTI: Tenofovir DF (TDF) TDF TDF
NRTI: Truvada (FTC+TDF) TVD FTC TDF
COBI/RTV/RPV containing ARVNRTI/INI: Stribild 
(EVG+COBI+FTC+TDF)STB EVG COBI FTC TDF
NRTI/NNRTI: Complera 
(FTC+RPV+TDF)CPA FTC RPV TDF
NNRTI: Rilpivirine (RPV) RPV RPV
PI: Kaletra (LPV+RTV) LPV/r LPV RTV
PI: Ritonavir (RTV) RTV RTV
Other COBI COBI
ABC containing ARV NRTI: Abacavir (ABC) ABC ABC
NRTI: Epzicom/Kivexa (ABC+3TC) EPZ ABC 3TC
NRTI: Trizivir (ABC+AZT+3TC) TZV ABC AZT 3TC
FTC containing ARVNRTI/INI: Stribild 
(EVG+COBI+FTC+TDF)STB EVG COBI FTC TDF
NRTI/INI: Genvoya 
(EVG+COBI+FTC+TAF )E-C-F-
TAFEVG COBI FTC TAF
NRTI/NNRTI: Atripla 
(EFV+FTC+TDF)ATR EFV FTC TDF
NRTI/NNRTI: Complera 
(FTC+RPV+TDF)CPA FTC RPV TDF
NRTI: Emtricitabine (FTC) FTC FTC
NRTI: Truvada (FTC+TDF) TVD FTC TDF
3TC containing ARV NRTI: Lamivudine (3TC) 3TC 3TC
NRTI: Epzicom/Kivexa (ABC+3TC) EPZ ABC 3TC
NRTI: Trizivir (ABC+AZT+3TC) TZV ABC AZT 3TC
NRTI: Combivir (AZT+3TC) CBV AZT 3TC
FTC containing ARVNRTI/INI: Stribild 
(EVG+COBI+FTC+TDF)STB EVG COBI FTC TDF
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 74 02 December 201913) Last Dose Dates and Last Study  Date:
a)Last Dose Date i s defined in SAP Section 3.8.1. I f the last dose date is incomplete or 
missing, the last dose date will be imputed as follows , using E/C/F/TAF or B/F/TAF 
dosing information as appropriate
:
If the last dose date is missing day (ie, month and y ear of the last dose are known), 
the latest of dispensing dates of stud y drug bottles, study drug start dates and end 
dates, and imputed last dose date (day  imputed as 15) will be used to impute the 
lastdose date. However ,if the month of the dispensing date is after the month of the 
last dose date, data query is needed. If subject died and the death date is complete 
(ie,not partial date) and before the imputed last dose date, the complete death date 
should be used as the imputed last dose date. 
If the last dose date is missing day  and month or completely  missing (eg, due to lost 
to follow -up), the latest of study  drug start dates and end dates, c linical visit dates, 
and laboratory  visit dates (excluding the date of 30 -day follow -up visit date) will be 
used to impute the last dose date. 
b)Last Stud y Date is the maximum of nonmissing study drug start dates and end dates, 
clinic visit and laboratory  visit dates, in cluding the 30 -day follow -up visit date for 
subjects who prematurely  discontinued study  or who completed study  according to study  
completion eCRF. Please note :if study  drug start date or end date is partially  missing, the 
imputed date (day imputed as 15) will be used. If subject died and the death date is 
complete (ie, not partial date) and before the imputed last study  date, the complete death 
date should be used as the imputed last study  date. Note that last visit date and last lab 
date include the 30- day follow -up visit.
14)Toxicity  Grades:
a)With regards to Trigl ycerides and Hy percholesterolemia, if the fasting status is not ‘Y’, 
in other words it is blank or ‘N’, then the lab result value would not be graded as 
non-fasting values are not inter pretable.
b)For toxicity  grade summary , we will include all postbaseline graded results up to 30 days 
after the last dose of study  drug, not just those at summarized visits.
15)
Clarification of the following LOCF algorithms:
Baseline va lues wil l not becarried for ward.
For CD4: If a value is missing in an analysis visit window, replace the missing value with 
the last on
-treatment value observed before the analy sis visit window that has the 
missing value.
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 75 02 December 201916)For safet y ECGs at postbaseline visits, the most conservative (worst) value within the 
window will be selected, eg, abnormal will be selected over normal for safety  ECG or 
clinical lysignificant abnormal will be selected over not clinical lysignificant nor mal if there 
are multiple abnormal findings.
17)Treatment -Emergent Adverse Events 
Events with Missing Onset Day and/or Month
The event is treatment emergent for the E/C/F/TAF phase if the following 3 criteria are met:
The month and y ear (or year) of onset da te is the same as or after the month and y ear 
(oryear) of the first dose of E/C/F/TAF study  drug, and
The month and y ear (or year) of the onset date is the same as or before the month and 
year (or y ear) of the date corresponding to the minimum of (1) the last dose of 
E/C/F/TAF study  drug plus 30 day s AND (2) the first dose of B/F/TAF study  drug minus 
1 day, and
End date is as follows: 
The (complete) end date is on or after the first E/C/F/TAF dose date, or
The month and y ear (or year) of end date is the s ame or after the month and year 
(oryear) of the first dose of E/C/F/TAF study  drug, or
End date is completel y missing
The event is treatment emergent for the B/F/TAF OL  extension phase if the following 3 
criteria are met:
The month and year (or year) of onset date is after the month and y ear (or year) of the 
first dose of B/F/TAF study  drug, and
The month and y ear (or year) of the onset date is the same as or before the month and 
year (or y ear) of the date corresponding to the last dose of B/F/TAF study  drug plus 
30days, and
End date is as follows: 
The (complete) end date is on or after the first B/F/TAF dose date, or
The month and y ear (or year) of end date is the same or after the month and year 
(oryear) of the first dose of B/F/TAF study  drug, or
End date is completel y missing
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 76 02 December 2019Events with Completely Missing Onset Date
An AE with a completely missing onset date is defined as TEAE for the E/C/F/TAF phase 
ifend date is as follows:
The (complete) end date is on or after the first E/C/F/TAF dose date, or
The month and year (or year) of end date is the same or after the month and y ear (or year) 
of the first dose of E/C/F/TAF study  drug, or
End date is completel y missing
18)Calculation of ratios 
To calculate laboratory  ratios (eg, fasting total cholesterol to HDL ratio), lab value of each 
test in the ratio needs to be from the same accession number; if any  test value used for the 
ratio calculation from the same accession number is missing, t he ratio is not calculable 
(ie,missing).
19)Graded Laboratory Abnormalities Summary
The following labels will be used for treatment -emergent laboratory  abnormalities and 
treatment -emergent Grade 3 or 4 laboratory  abnormalities summary  tables and listings:
BatteryLab Test Label 
Used in l -labtox ListingToxicity 
DirectionLab T est Label
Used in t-labtox Table
HematologyHemoglobin Decrease Hemoglobin (Decreased)
Neutrophils Decrease Neutrophils (Decreased)
Platelets Decrease Platelets (Decreased)
WBC Decrease WBC (Decreased)
ChemistryAlbumin Decrease Albumin (Decreased)
Alkaline Phosphatase Increase Alkaline Phosphatase (Increased)
ALT Increase ALT (Increased)
Amylase Increase Amylase (Increased)
AST Increase AST (Increased)
Bicarbonate Decrease Bicarbonate (Decreased)
Corrected Calcium Increase Corrected Calcium (Hypercalcemia)
Corrected Calcium Decrease Corrected Calcium (Hypocalcemia)
Creatine Kinase (CK) Increase Creatine Kinase (Increased)
Creatinine Increase Creatinine (Increased)
GGT Increase GGT (Increased)
Lipase Increase Lipase (Increased)
Magnesium Decrease Magnesium (Hypomagnesemia)
Phosphate Decrease Phosphate (Hypophosphatemia)
Serum Glucose (Fasting) Increase Serum Glucose (Fasting, Hyperglycemia)
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 77 02 December 2019BatteryLab Test Label 
Used in l -labtox ListingToxicity 
DirectionLab T est Label
Used in t-labtox Table
Serum Glucose (Fasting) Decrease Serum Glucose (Fasting, Hypoglycemia)
Serum Glucose (Nonfasting) Increase Serum Glucose (Nonfasting, Hyperglycemia)
Serum Glucose (Nonfasting) Decrease Serum Glucose (Nonfasting, Hypoglycemia)
Serum Potassium Increase Serum Potassium (Hyperkalemia)
Serum Potassium Decrease Serum Potassium (Hypokalemia)
Serum Sodium Increase Serum Sodium (Hypernatremia)
Serum Sodium Decrease Serum Sodium (Hyponatremia)
Total Bilirubin Increase Total Bilirubin (Hyperbilirubinemia)
Total Cholesterol (Fasting) Increase Total Cholesterol (Fasting, Hypercholesterolemia)
Triglycerides (Fasting) Increase Triglycerides (Fasting, Increased)
LDL (Fasting) Increase LDL (Fasting, Increased)
Urea Nitrogen (BUN) Increase Urea Nitrogen (Increased)
Uric Acid Increase Uric Acid (Hyperuricemia)
Uric Acid Decrease Uric Acid (Hypouricemia)
20)Concomitant nonstudy -drug ARV medications (ie, ARV medications other than study  drug 
that are taken while receiving stud y drug) will be flagged in “Nonstud y-Drug Antiviral 
Medication” listing. The logic to define concomitant nonstudy -drug ARV is similar to 
concomitant non -ARV Medications (see details in Section 8.6.2)
21)Lipid modify ing medication analy ses:
Lipid modify ing medication is defined to be the concomitant medication with ACLAS  
“LIPID MODIFYING AGENTS” and CMDECOD contains wording of “STATIN” in the 
ADCM dataset.
Subjects who took lipid modify ing medications at study  entry refer to the subjects who 
have any use of the lipid modifying agents at study day 1 (ie, the first E/C/F/TAF 
dose 
date).
a)More specificall y, subjects with “L ipid Modify ing Agent Use at Study  Entry ” include 
those subjects in E/C/F/TAF S afety  Ana lysis set meeting both the following criteria: 
1)any selected CM record with the start date ≤ the first E/C/F/TAF dose date, and 
2)the end date of the selected CM record ≥the first E/C/F/TAF dose date or the end 
date of the selected CM record is ongoing
b)For lipid modify ing medications with the start date completely  unknown, we assume 
the start date is on or before the E/C/F/TAF first dose date, lipid modify ing 
medication was considered as being taken at study entry  if the end date is not prior to 
the fi rst E/C/F/TAF dose date (ie, the end date is on or after the first E/C/F/TAF dose 
date, co mpletel y unknown, or ongoing).
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 78 02 December 2019c)Lipid modify ing medications with the start date prior to the first E/C/F/TAF dose date 
and the end date unknown (completel y missing) we re considered as being taken at 
study  entry  (the unknown end date is assumed on or after the first E/C/F/TAF dose 
date).
Subjects who initiated lipid modifying medications during the E/C/F/TAF phase refer sto 
the subjects in the E/C/F/TAF S afety  Analysis set who did not take lipid modify ing 
medications at study  entry  and met the following criteria: 1) any  selected CM record 
started after the first E/C/F/TAF dose date and on and prior t o the last E/C/F/TAF dose 
date.
Subjects who took lipid modify ing medicat ions at the start of the B/F/TAF OL extension 
phase refer to the subjects who have any use of the lipid modify ing agents at B/F/TAF 
Study  Day 1 (ie, the first B/F/TAF dose date).
d)More specificall y, subjects with “L ipid Modify ing Agent Use at Entry  in B/F/TAF 
OL Extension Phase ” include those subjects in the B/F/TAF S afety  Analysis set 
meeting both the following criteria: 1) any selected CM record with the start date 
≤the first B/F/TAF dose date, and 2) the end date of the selected CM 
record ≥thefirst B/F/TAF dose date or the end date of the selected CM record is 
ongoing 
e)For lipid modify ing medications with the start date completely  unknown, we assume 
the start date is on or before the B/F/TAF first dose date, lipid modifying medication 
was considered as being taken at start of B/F/TAF OL extension phase if the end date 
is not prior to the first B/F/TAF dose date (ie, the end date is on or after the first 
B/F/TAF dose date, co mpletely  unknown, or ongoing).
f)Lipid modify ing medications with the start date prior to the first B/F/TAF dose date 
and the end date unknown (completel y missing) were considered as being taken at the 
start of the B/F/TAF OL extension phase (the unknown end date is assumed on or 
after the first B/F/TAF dose date).
Subjects who initiated lipid modify ing medications during the B/F/TAF OL extension
phase refer sto the subjects in the B/F/TAF S afety Analy sis set who did no
t take lipid 
modify ing medications at the start of the B/F/TAF OL extension phase and met the 
following cri teria: 1) an y selected CM record started after the first B/F/TAF dose date 
and on and prior t o the last B/F/TAF dose date.
22)For figures, if at a visit where n (sample size) for any  treatment group ≤ 5, data for that 
treatment group will not be display ed at the vis it in figure (except the Kaplan
-Meier figure), 
but all data will be included in the corresponding table summary .
Genvoya /Biktarvy
GS-US-292-1825
Statistical Analysis Plan Version 1
CONFIDENTIAL Page 79 02 December 201923) LDL: Conversions between 2nd and 3rd generations
LDL was anal yzed by 2 different assay s in the s tudy: 2nd generation ( RCT2394) and 
3rdgeneration (RCT3870). Samples collected at earlier vis its were anal yzed using LDL 
2ndgeneration assay. Samples collected at later vis its were anal yzed using L DL 
3rdgeneration assay. The conversion formulas are as follow:
2nd Gen (mmol/L )  (3rd Gen - 0.0626)/0.882
3rd Gen (mmol/L) 
 (0.882 x 2nd Gen) + 0.0626
For this anal ysis, since LDL  samples were analy zed by  2nd generation assay  at Baseline, 
only conversion from 3rd generation to 2nd generation will be performed .
For the anal ysis of change from baseli ne in fasting direct LDL: the sample anal yzed by LD
L 
3rd generation assay  will be converted to 2nd generation as a new record with test codes of 
LIP.LDL.00.02 in raw data. During ADaM stage, a derived parameter code (FLDL2) for
“Fasting LDL Cholesterol 2ND GEN Combined” will be generated to pool the records from 
both original and converted (LIP.LDL.00.02) 2nd generation results to calculate the change 
from baseline in fasting direct LDL.
For the anal ysis of toxicity  grade for fasting direct LDL: toxicity  grade will be based on the 
Gilead grading results (ie, toxgrg) from the original values before conversion. I n another 
words, during ADaM programming stage, a derived parameter code (FLDLTOX) for 
“Fasting LDL Cholesterol for Toxicity ” will be generat ed to poo l the records from 
2ndgeneration and 3rd generation to derive treatment -emergent toxicity grades, maximum 
postbaseline toxicity  grades, etc.
24) Plasma concentrations
During the B/F/TAF OL extension phase, at Weeks 4, 24, and 48, on the day of 
hemodialy sis, a sparse timed blood sample was to be collected from all subjects within 
10minutes prior to hemodialysis initiation. Predose (within 30 minutes prior to study  drug 
administration) blood draws for plasma samples were also collected at these visits. For the 
summary  table, all values will be listed; however only  trough values willbe included in the 
summary  statistics. Values not included in the summary  statistics should be flagged
.
In general, intensive PK concentration values that are BLQ will be treated as 0 at predose 
timepoints and one -half the value of the LLOQ at postdose time points for summary  
purposes . Other PK concentration values ( including trough, predose, postdose, any time PK 
concentration )that are BLQ will be treated as one -half of the LLOQ.
SAP Final GS-US-292-1825
ELECTRONIC SIGNATURES
Signed by Meaning of Signature Server Date
(dd-MMM-
yyyy hh:mm:ss)
Project Team
Leader eSigned03-Dec-2019
11:13:38
Biostatistics eSigned 03-Dec-2019
17:27:06
Project Team
Leader eSigned05-Dec-2019
01:44:24
PPD
PPD
PPD--